CA1341595C - Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques - Google Patents
Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniquesInfo
- Publication number
- CA1341595C CA1341595C CA000617095A CA617095A CA1341595C CA 1341595 C CA1341595 C CA 1341595C CA 000617095 A CA000617095 A CA 000617095A CA 617095 A CA617095 A CA 617095A CA 1341595 C CA1341595 C CA 1341595C
- Authority
- CA
- Canada
- Prior art keywords
- fact
- procedure according
- host cells
- stochastic
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 261
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 223
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 178
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 141
- 238000000034 method Methods 0.000 title claims abstract description 133
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 95
- 108020004414 DNA Proteins 0.000 title claims description 77
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 44
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 44
- 239000002157 polynucleotide Substances 0.000 claims abstract description 44
- 238000012216 screening Methods 0.000 claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 230000002906 microbiologic effect Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 115
- 150000001875 compounds Chemical class 0.000 claims description 52
- 239000013604 expression vector Substances 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 230000015572 biosynthetic process Effects 0.000 claims description 32
- 230000006870 function Effects 0.000 claims description 28
- 238000003786 synthesis reaction Methods 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 230000010076 replication Effects 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 108010093031 Galactosidases Proteins 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 230000003197 catalytic effect Effects 0.000 claims description 10
- 102000002464 Galactosidases Human genes 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000005758 transcription activity Effects 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 230000004071 biological effect Effects 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 108020004566 Transfer RNA Proteins 0.000 claims description 4
- 108020005202 Viral DNA Proteins 0.000 claims description 4
- 238000007334 copolymerization reaction Methods 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 230000001276 controlling effect Effects 0.000 claims description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 3
- 230000008827 biological function Effects 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 238000009776 industrial production Methods 0.000 claims 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims 1
- 239000013598 vector Substances 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000006116 polymerization reaction Methods 0.000 description 12
- 230000002194 synthesizing effect Effects 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000009088 enzymatic function Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000008826 genomic mutation Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- MTEUMURLJRZUKD-UHFFFAOYSA-N acetic acid;butan-1-ol;pyridine;hydrate Chemical compound O.CC(O)=O.CCCCO.C1=CC=NC=C1 MTEUMURLJRZUKD-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012455 bioassay technique Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003136 immunomodifying effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.
Description
MARC BALLIVET AND STUART KAUFFMAN
PROCEDURE FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTIDES, OR PROTEINS BY RECOMBINANT DNA TECHNIQUES
This application is a division of our prior Canadian Patent Application Serial No. 504,653, filed March 20. 1986.
The present invention has as its object a procedure to obtain DNA, RNA, peptides, polypeptides or proteins, through use of transformed host cells containing genes capable of expressing these RNAs, peptides, polypeptides, or proteins: that is to say, by utilization of recombinant DNA techniques.
The invention aims at the production of stochastic genes or fragments of stochastic genes in a fashion to permit obtaining simultaneously, after transcription and translation of these genes, a very large number (on the order of at least 10.000) of completely new proteins or hybrids with known proteins, in the presence of host cells (bacterial or eucaryotic) containing the genes capable of expressing these proteins, and to carry out thereafter a selection or screen among the said clones, in order to determine which of them produce proteins with desired properties, for example structural, enzymatic, catalytic, antigenic. pharmacologic, or properties of liganding, and more generally, chemical, biochemical, biological, etc. properties. Thereafter the invention aims at improvement of the desired function by modification of the said stochastic genes, or modification of the products of the said genes.
The invention equally has as its aim procedures to obtain, and then improve, sequences of DNA or RNA with utilizable properties, notably chemical, biochemical, or biological properties.
It is clear, therefore, that the invention is open to a very large number of applications in very many areas of science, industry and medicine.
The procedure for production of peptides or polypeptides according to the invention is characterized in that one produces simultaneously, in the same medium, genes which are at least partially composed of synthetic stochastic polynucleotides, that one introduces the genes thus obtained into host cells, that one cultivates simultaneously the independent clones of the transformed host cells containing these genes in such a manner so as to clone the stochastic genes and to obtain the production of the proteins expressed by each of these stochastic genes, that one carries out selection and/or screening of the clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one desired activity, that one thereafter isolates the clones thus identified and that one cultivates them to produce at least one peptide or polypeptide having the said property.
Where improvement of the desired property is sought, the procedure involves modification of the genes producing the identified peptides, followed by recloning the said genes, and selection or screening the
PROCEDURE FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTIDES, OR PROTEINS BY RECOMBINANT DNA TECHNIQUES
This application is a division of our prior Canadian Patent Application Serial No. 504,653, filed March 20. 1986.
The present invention has as its object a procedure to obtain DNA, RNA, peptides, polypeptides or proteins, through use of transformed host cells containing genes capable of expressing these RNAs, peptides, polypeptides, or proteins: that is to say, by utilization of recombinant DNA techniques.
The invention aims at the production of stochastic genes or fragments of stochastic genes in a fashion to permit obtaining simultaneously, after transcription and translation of these genes, a very large number (on the order of at least 10.000) of completely new proteins or hybrids with known proteins, in the presence of host cells (bacterial or eucaryotic) containing the genes capable of expressing these proteins, and to carry out thereafter a selection or screen among the said clones, in order to determine which of them produce proteins with desired properties, for example structural, enzymatic, catalytic, antigenic. pharmacologic, or properties of liganding, and more generally, chemical, biochemical, biological, etc. properties. Thereafter the invention aims at improvement of the desired function by modification of the said stochastic genes, or modification of the products of the said genes.
The invention equally has as its aim procedures to obtain, and then improve, sequences of DNA or RNA with utilizable properties, notably chemical, biochemical, or biological properties.
It is clear, therefore, that the invention is open to a very large number of applications in very many areas of science, industry and medicine.
The procedure for production of peptides or polypeptides according to the invention is characterized in that one produces simultaneously, in the same medium, genes which are at least partially composed of synthetic stochastic polynucleotides, that one introduces the genes thus obtained into host cells, that one cultivates simultaneously the independent clones of the transformed host cells containing these genes in such a manner so as to clone the stochastic genes and to obtain the production of the proteins expressed by each of these stochastic genes, that one carries out selection and/or screening of the clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one desired activity, that one thereafter isolates the clones thus identified and that one cultivates them to produce at least one peptide or polypeptide having the said property.
Where improvement of the desired property is sought, the procedure involves modification of the genes producing the identified peptides, followed by recloning the said genes, and selection or screening the
-2-transformed cells to identify those producing at least one peptide or polypeptide with improved function. It also includes rnodification of the protein product itself.
In a first means to utilize this procedure, stochastic genes are produced by stochastic copolymerization of the four kinds of deoxyphosphonucleoti des - A,C,G and T from the two ends of an initially linerized expression vector, foilowed by formation of cohesive ends In such a fashion as to form a stochastic first strand of DNA constituted by a molecule of expression vector possessing two stochastic sequences whose 3' ends are complementary, followed by the synthesis of the second strand of the stochastic DNA.
In a second mode to utiiize this procedure, stochastic genes are produced by copolymerization of oligonucleotides without cohesive ends, i n a manner to form fragments of stochast ic DNA, fol l owed by ligation of these fragments to a previously linearized expression v ector .
The expression vector can be a plasmid, notably a bacterial plasmid. Excellent results have been obtained using the plasmid pUC8 as the expression vector.
The expression vector can also be viral DNA or a hybrid of plasmid and viral DNA.
The host cells can be prokaryotic cells such as HB 101 and C 600, or eukaryotic cells.
When uti I iz ing the procedure according to the second mode mentioned above, it is possible to utilize ol igonucleotides which form a group of palindromic octamers.
Particularly good results are obtained by utilizing the following group of palindromic octamers:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' C;!,TAJ GG 3' 5' CATCGATG 3' It is possible to use oligonucieotides which form a group of pal indromic heptamers.
Good results are obtained utifizing the following group of palindromic heptamers:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X= A, G, C, or T, and R A or T
According to a method to utilize these procedures which is particularly advantageous, one isolates and purifies the
In a first means to utilize this procedure, stochastic genes are produced by stochastic copolymerization of the four kinds of deoxyphosphonucleoti des - A,C,G and T from the two ends of an initially linerized expression vector, foilowed by formation of cohesive ends In such a fashion as to form a stochastic first strand of DNA constituted by a molecule of expression vector possessing two stochastic sequences whose 3' ends are complementary, followed by the synthesis of the second strand of the stochastic DNA.
In a second mode to utiiize this procedure, stochastic genes are produced by copolymerization of oligonucleotides without cohesive ends, i n a manner to form fragments of stochast ic DNA, fol l owed by ligation of these fragments to a previously linearized expression v ector .
The expression vector can be a plasmid, notably a bacterial plasmid. Excellent results have been obtained using the plasmid pUC8 as the expression vector.
The expression vector can also be viral DNA or a hybrid of plasmid and viral DNA.
The host cells can be prokaryotic cells such as HB 101 and C 600, or eukaryotic cells.
When uti I iz ing the procedure according to the second mode mentioned above, it is possible to utilize ol igonucleotides which form a group of palindromic octamers.
Particularly good results are obtained by utilizing the following group of palindromic octamers:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' C;!,TAJ GG 3' 5' CATCGATG 3' It is possible to use oligonucieotides which form a group of pal indromic heptamers.
Good results are obtained utifizing the following group of palindromic heptamers:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X= A, G, C, or T, and R A or T
According to a method to utilize these procedures which is particularly advantageous, one isolates and purifies the
-3- 13 4~595 transforming DNA of the plasmids from a culture of independent clones of the transformed host cells obtained by following the procedures above, then these plasmids are cut by at least one restriction enzyme corresponding to a specific restriction cutting site present in the palindromic octamers or heptamers but absent from the expression vector which was utilized; this cutting is followed by inactivation of the restriction enzyme, then one simultaneously treats the ensemble of linearized stochastic DNA
fragments thus obta i ned w i th T4 DNA I igase, i n such a manner to create a new ensemble of DNA containing new stochastic sequences, this new ensemble can therefore contain a number of stochastic genes larger than the number of genes in the initial ensemble.
One then utilizes this new ensemble of transforming DNA to transform the host cells and clone these genes, and finally utilizes screening and/ or selection and isolates the new clones of transformed host cells and finally these are cultivated to produce at least one pept i de or polypept i de, for example, a new protein, having a desired property.
Any other means to generate and clone stochastic DNA sequences so as to obtain their expression as novel peptides, polypeptides, or proteins, or their expression as the novel portion of a fusion protein, followed by screening or selection for a desired property and obtaining at least one clone producing a peptide with the desired property, can be used according to the Invention.
The property serving as the criterion for selection of the clones of host cells.can be the capacity of the peptides or polypeptides, produced by a given clone, to catalyse a given chemical reaction.
Further, for the production of several peptides and or polypeptides, the said property can be the capacity to catalyse a sequence of reactions leading from an initial group of chemical compounds to at least one target compound.
With the aim of producing an ensemble constituted by several or many peptides and or polypeptides which are reflexively autocatalytic, the said proprety can be the capacity to catalyse the synthesis of the same ensemble from amino acids and/ or ol igopeptides in an appropriate milieu.
The said property can also be the capacity to modify selectively the biological or chemical properties of a given compound, for example, the capacity to selectively modify the catalytic activity of a polypeptide.
The said property can also be the capacity to simulate, Inhibit, or modify at least one biological function of at least one biologically active compound, chosen, for example, among t;rE
hormones, neurotransmitters, adhesion factors, growth factors and specific regulators of DNA replication and/or transcription and/
or trans l at i on of RNA.
The said property can equally be the capacity of the peptide or polypeptide to bind to a given (igand.
-a- 4 1 5 9~-The Invention also has as its object the use of the peptide or polypeptide obtained by the procedures specified above, for the detection and/ or the titration of a ligand.
According to a particularly advantageous mode of utilization, the criterion for selection of the clones of transformed host cells is the capacity of these peptides or polypeptides to simulate or modify the effects of a biologically active molecule, for example, a protein; screening and/or selection for clones of transformed host cells producing at least one peptide or polypeptide having this property,is carried out by preparing or obtaining antibodies against the the active mol ecu I e, then uti I iz ing these antibodies after their purification, to identify the clones containing peptides or polypeptides which are bound by the said antibodies against the active molecule, then by cultivating the clones thus identified, separating and purifying the peptide or polypeptide produced by these clones, and finaliy by submitting the peptide or polypeptide to an in vitro assay to verify that it has the capacity to simulate or modify the effects of the said mol ecu I e.
The capacity to simulate or modify the effects of the said mol ecu i e by the stochast i c pept i de can be improved by modi f i cat i on of the gene coding for that peptide, retransformation of the host cells by the modified genes, and selection or screening for those modifications which improve the desired function. In addition, the said peptide can be modified chemicaliy, or derivatized, to improve its function.
According to this means to utilize the procedures according to the invention, the proper ty serving as the criterion of selection is that of havi ng at least one epitope s im i I ar to one of the epitopes of a given antigen.
The invention carries over to obtaining polypeptides by the procedure specified above and utilizable as chemotherapeutically active substances.
In particular, in the case where the said antigen is EGF, the invention permits obtaining polypeptides usable for chemotherapeutictreatment of epitheliomas.
The invention also appi ies to a use of the procedure specified above for the preparation of a vaccine; the application is characterized by the fact that antibodies against the pathogenic agent are i sol ated, for example anti bodi es formed after i njecti on of the pathogenic agent in the body of an animal capable of forminc antibodies against this agent, and these antibodies are used to identify the clones producing at least one protein having at least one epitope similar to one of the epitopes of the pathogenic agent, the transformed host cell corresponding to these clones are cultured to produce these proteins, this protein(s) is isolated and purified from the clones of cells, then this protein(s) is used for the production of a vaccine against the pathogenic agent. The identified proteins can, as above, be improved by modifications (eg. mutagenizing) of the stochastic genes coding for the said proteins, retransformation of those genes i nto appropriate host cei I s expressing the modi f ied 1341 a95 proteins, rescreening or selection of those with improved capacity to be bound by antibodies against the initial antigenic agent, and use of these improved proteins to produce a vaccine.
For example, in order to prepare an anti-HVB vaccine, one can extract and purify at least one capside protein of the HVB virus inject this protein into an animal capable of forming antibodies against this protein, recover and purify the antibodies thus formed, utilize these antibodies to identify the clones producing at least one protein having at least one epitope sim i I ar to one of the epitopes of the HVB virus, then cu l tivate the clones of transformed host cells corresponding to these clones in a manner to produce this protein(s), isolate and purify the protein(s) from the culture of these clones of cells and utilize the protein(s) for the production of an anti HVB vaccine.
According to a variant of the procedure, one identifies and isolates the clones of transformed host cells producing peptides or polypeptides having the property desired, by affinity chromatography against antibodies corresponding to a protein expressed by the natural part of the DNA hybrid.
For e;kample, in the case where the natural part of the hybrid DNA
contains a gene expressing B- galactosidase, one can advantageously Identify and isoiate the said clones of transformed host cells by affinity chromatography against anti B
galactosidase antibodies.
After expression and purification of hybrid peptides or polypeptides, one can separate and isolate their novel parts.
According to the invention, a means of utilizing the procedure is to screen or select for novel peptides polypeptides or proteins catalysing a given chemical reaction.
According to an advantageous means of utilizing the procedures according to the invention, the host cells consist in bacteria such as Escherichia coli whose genome contains neither the natural gene expressing B galactosidase, nor the EBG gene, that is to say, Z-,EBG- E coli. The tranformed cells are cultured in the presence of X gal and the indicator IPTG in the medium, and cells positive for B galactosidase functions are detected;
thereafter, the transforming DNA is transplanted into an appropriate clone of host cel I s for large scale culture to produce at least one peptide or polypeptide with B galactoasidase activity.
The property serving as the criterion for selection of the tranformed host cells can also be the capacity of the polypeptides or proteins produced by the culture of these clones to bind to a given compound.
This compound can be chosen advantagousely among peptides, polypeptides and proteins, notably among proteins regulating the transcription activity of DNA.
The invention has also as its object those proteins which are obtained in the case where the property serving as criterion of sel ecti on of the clones of transformed host cei 1 s consists in the capacity of these proteins to bind to regulatory proteins controlling transcription activity or replication of the DNA.
On the other hand, the said compound which is bound can also be chosen among DNA and RNA sequences.
The invention has,in addition, as an object obtaining a protein which is able to bind to DNA sequences which act as cis regulatory sequences controlling replication or transcription of neighboring DNA sequences, and by binding modify the transcription or replication of the neighboring DNA sequence. Equally the invention has as an object obtaining a protein which is able to bind to an RNA sequence and thereby control translation from that RNA or the stabiIity of the RNA.
The aim of the invention includes utilization of proteins obtained in the second case mentioned to modify the properties of transcription or replication of a sequence of DNA, in a cell containing the sequence of DNA, and expressing this protein.
The invention has as its object as weli a procedure to produce DNA, characterized by simultaneous production in the same medium, of genes at least partialiy composed of stochastic synthetic polynucleotides, that the genes thus obtained are introduced into host cel I s to produce an ensemb l e of transformed host cel 1 s, that screening and/or selection on this ensemble is carried out to i dent i fy those host ce l l s conta i n i ng stochast i c sequences of DNA
having at least one desired property , and finally, that the DNA
from the clones of host cells thus identified is isolated. The properties of the identified DNA can be improved by modification of the stochastic genes, eg through a variety of mutagenesis procedures known in themselves or described below, recioning into an appropriate vector, transformation of appropriate host cells, foi 1 owed by screen i ng or se i ect i on for an improved level of the desired property.
The invention also has as its object a procedure to produce RNA, characterized by simultaneous production in the same medium, of genes at least *partially composed of stochastic synthetic polynucleotides, that the genes thus obtained are introduced into host cells to produce an ensemble of transformed host cells, that the host cells so produced are cultivated simultaneously, and screening and/or selection of this ensemble is carried out in a manner to identify those host cells containing stochastic sequences of RNA having at least one desired property, and that the RNA be Isolated from the host cells thus identified. As above, the properties of the RNA thus Isolated can be Improved by modification of the corresponding stochastic genes, retransformation and reselection or rescreening.
The said property can be, the capacity to bind to a given compound, which might be for example a peptide or polypeptide or protein, or also the capacity to catalyse a given chemical reaction, or the capacity to be a transfer RNA.
In one aspect, the present invention provides a procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.
In another aspect, the present invention provides a method of detecting or titrating a ligand, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells: (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides: (d) screening said population of peptides or polypeptides for capacity to bind to a ligand; (e) contacting said peptide or polypeptide identified in step (d) with a sample suspected of containing said ligand. and (f) determining binding of said peptide or polypeptide to said ligand, wherein binding indicates the presence or amount of said ligand in said sample.
In yet another aspect, the present invention provides a method of inducing pharmacologic or chemotherapeutic action, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to selectively modify a chemical or biological property of a compound, and (e) contacting said peptide or polypeptide identified in step (d) with a sample suspected of containing said compound under conditions sufficient to selectively modify the chemical or biological effects of said compound.
In still yet another aspect, the present invention provides a method of diminishing the in vitro or in vivo concentration of antibodies specific for an antigen, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides: (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially ~-.
7a- 1341595 stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for at least one epitope similar to an epitope of an antigen, and (e) contacting said peptide or polypeptide identified in step (d) with a sample containing antibodies specific for said antigen under conditions sufficient for selective binding of said peptide or polypeptide and said antibodies.
In still yet another aspect, the present invention provides a method of preparing an agent for suppression of immunological hypersensitivity, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to selectively modify a chemical or biological property of a compound or for containing at least one epitope similar to an epitope of an antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having immunological hypersensitivity suppression activity.
In still yet another aspect, the present invention provides a method of preparing an agent for inducing tolerance, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides;
(b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for containing at least one epitope similar to an epitope of an antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having tolerance inducing activity.
In still yet another aspect, the present invention provides a method of preparing an agent for chemotherapeutic treatment of epitheliomas, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for at least one epitope similar to an epitope of an EGF antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having chemotherapeutic action against epitheliomas.
In still yet another aspect, the present invention provides a method of producing a selective binding peptide, polypeptide, protein, DNA or RNA
composition, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said ;,,.,' 7b- 13415 95 population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to bind to a compound, said compound comprising peptide, polypeptide, protein, DNA or RNA, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium.
In still yet another aspect, the present invention provides a procedure to produce DNA characterized by the fact that, in the same milieu, genes which are at least partially composed of stochastic synthetic polynucleotides are produced, that the genes so produced are introduced into host cells in a manner to produce an ensemble of transformed host cells, that these are grown so as to produce independent clones of the host cells so produced, that screening and/or selection is carried out on this ensemble to identify those host cells which contain those stochastic sequences of DNA having at least one desired property, and that such DNA is isolated from the identified cultures of the host cells.
In still yet another aspect, the present invention provides a method of modulating replication or transcription activity of a polynucleotide, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) culturing said host cells to produce independent clones containing said at least partially stochastic synthetic polynucleotides; (d) screening said at least partially stochastic synthetic polynucleotides for capacity to bind to a peptide, polypeptide or protein regulating transcription or replication of DNA, and (e) linking said at least partially stochastic synthetic polynucleotide identified in step (d) with a sequence of DNA, wherein said at least partially stochastic synthetic polynucleotide provides a cis-regulatory sequence having the capacity to modulate transcription or replication of said DNA.
In still yet another aspect, the present invention provides a method of modulating the activity of a cis-regulatory sequence of replication or transcription, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides: (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) culturing said host cells to produce independent clones containing said at least partially stochastic synthetic polynucleotides; (d) screening said at least partially stochastic synthetic polynucleotides for capacity to bind to a peptide, polypeptide or protein regulating transcription or replication of DNA, and (e) contacting said at least partially stochastic synthetic polynucleotides identified in step (d) with a sample containing said peptide, polypeptide or protein regulating transcription or replication of DNA
under conditions sufficient for selective binding, wherein said , ~õ.s 7c- 13-41595 selective binding of said at least partially stochastic synthetic polynucleotide modulates the transcription or replication activity of said peptide, polypeptide or protein.
In still yet another aspect, the present invention provides a procedure for the production of RNA, characterized by the fact that, in the same milieu, genes which are at least partially composed of synthetic stochastic polynucleotides are produced simultaneously, that the genes thus obtained are introduced in host cel l s in a manner to produce a n ensemble of transformed host cells, that the independent clones of transformed host cells so produced are grown simultaneously, that a screening and/or selection is carried out on this ensemble in a manner to identify those host cells which containing stochastic sequences of RNA having at least one desired property, and that the RNA is isolated from the cultures of host cells so identified.
First, we shall describe particularly useful procedures to carry out the synthesis of stochastic genes, and the introduction of those genes in bacteria to produce clones of transformed bacteria.
1) Direct synthesis on an expression vector.
a) Linearization of the vector.
30 micrograms, that is, approximately 1013 molecules of the pUC8 expression vector are linearized by incubation for 2 hours at 37 C with 100 units of the Pstl restriction enzyme in a volume of 300u1 of standard buffer for that enzyme. The linearized vector is treated with phenol-chloroform then precipitate in ethanol, taken up in a volume of 30 ul and loaded onto a 0.8% agarose gel in standard TEB buffer. After migration in a field of 3V/cm for three hours, the linearized vector is electro-eluted, precipitated in ethanol, and taken up in 30 ul of water.
b) Stochastic synthesis using the enzyme Terminal Transferase (TdT).
30 ug of the linearized vector are reacted with 30 units of TdT in 300 ul of the appropriate buffer, in the presence of 1mM dGTP, 1mM dCTP, 0.3 mM dTTP and 1 mM dATP. The lower concentration of dTTP is chosen in order to reduce the frequency of "stop" codons in the corresponding messenger RNA. A similar result, although somewhat less favorable, can be obtained by utilizing a lower concentration for dATP than for the other desoxynucleotide triphosphates. The progress of the polymerization on the 3' extremities of the Pstl sites is followed by analysis on a gel of aliquots taken during the course of the reaction.
When the reaction attains or passes a mean value of 300 nucleotides added per 3' extremity, it is stopped and the free nucleotides are separated from the polymer by differential precipitation or by passage over a column containing a molecular sieve such as Biogel*P60. After *Trade Mark :;ti T
7 d - 1 3 4 1 5 95 concentration by precipitation in ethanol, the polymers are subjected to a further polymerization with TdT, first in the presence of dATP, then in the presence of dTTP. These last two reactions are separated by a filtration on a gel and are carried out for short intervals (30 seconds to 3 minutes) in order to add sequentially 10-30 A followed by 10-30 T
to the 3' ends of the polymers.
c) Synthesis of the second strand of the stochastic DNA
Each molecule of vector possesses at the end of the preceeding operation, two stochastic sequences whose 3' ends are complementary.
The mixture of polymers is therefore incubated in conditions favoring hybridization of the complementary extremities st. ,~..
( 150mh1 NaCi , 10mM Tr i s-HCI , pH 7.6, 1 mN1 EDTA at 65 -C for 10 minutes, followed by lowering the temperature to 22 C at a rate of 3 to 4 C Per hour. The hybridized polymers are then reacted with 60 units of the large fragment (Kienow) of polymerase I, in the presence of the four nuc l eot i de tr i phosphates ( 200mh1) at 4 C for two hours. This step accomplishes the synthesis of the second strand from the 3' ends of the hybrid polymers. The molecules which result from this direct synthesis starting from linearized vector are thereafter utilized to transform competent cells.
d) Transformation of competent clones 100 to 200 ml of competent HB101 of C600 cells at a con.centration of 1010 cells/mi, are incubated with the stochastic DNA
preparation (from above) in the presence of 6mM CaC12, 6 mP-1 Tris-HCI pH8, 6 mP-i MgCl2 for 30 minutes at 0 C. A temperature shock of 3 minutes at 37 C is imposed on the mixture, followed by the addition of 400 to 800 ml of NZY culture medium, without ant i bi otics. The transformed cu l ture is Incubated at 37 C for 60 minutes, then diluted to 10 litres by addition of NZY medium containing 40 ug/ml of ampicillin. After 3 - 5' hours of incubation at 37 C, the amplified culture is centrifuged, and the pel I et of transformed cel I s i s lyophi lysed and stored at -70 C.
Such a culture contains 3 x 107' to 108, independent transformants, each containing a unique stochastic gene inserted into the expression vector.
II) Synthesis of stochastic genes starting from oligonucleotides w ithout cohesive ends.
This procedure is based on the fact that polymerization of judiciously chosen palindromic oligonucleotides permits construction of stochastic genes which have no "stop" codon in any of the six possible reading frames, whi l e at the same time assuring a balanced representation of triplets specifying all amino acids. Further, and to avoid a repetition of sequence motifs in the proteins which result while using only a small number of initial palindromic oligonucleotides, the oligonucleotides can contain a number of bases which is not a mul ti pi e of three. The example which fol I ows describes the use of one of the possible combinations which fulfil these criterio:
a) Choice of a group of octamers The group of oligonucleotides following:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' CCATATGG 3' 5' CATCGATG 3' Is composed of 5 paiindromes ( thus self complementary sequences) where it is easy to verify that their stochastic polymerization does not generate any "stop" codons, and specifies all the amino acids.
Obviously, one can utlIize other groups of palindromic octamers which do not generate any "stop" codons and specify all the amino acids found in polypeptides. Clearly, it is also possible to utilize non palindromic groups of octamers, or other oligomers, under the condition that their complements forming double stranded DNA are also used. Further it is possible to use more than 5 pal indromic octomers.
b) Assembly of an ensemble stochastic genes from a group of octamer s.
A mixture containing 5 ug of each of the oligonucleotides indicated above ( previously phosphorylated at the 5' position by a standard procedure) are reacted in a 100 ul volume containing 1 mM ATP, 10% polyethYl enegiycol, and 100 un i ts of T4 DNA I igase in the appropriate buffer at 13 C for six hours. This step carries out the stochastic polymerization of the oligomers in the double stranded state and without cohesive ends. The resulting polymers are isolated by passage over a molecular sieve (Biogel P60) recovering those with 20 to 100 oiigomers. After concentration, th i s f ract i on is aga i n su bm i tte d to cata i y s i s of po l y mer i z at i on by T4 DNA I igase under the condi ti ons described above. Thereafter, as described above, those polymers which have assembled at least 100 oligomers are i soi ated.
c) Preparation of the host pl asmi d The pUC8 express i on vector is 1 i near i zed by the Smal enzyme in the appropriate buffer, as described 9.~ove. The vector linearized by SP4a I does not have cohesive ends. Thus the linearized vector is treated by calf intesting alkaline phosphatase (CIP) at a level of one unit per microgram of vector in the appropriate buffer, at 37 C for 30 minutes. The CIP enzyme is thereafter inactivated by two successive extractions with phenol-choloform. The linearized and dephosphorylated vector is precipitated in ethanol, then redissolved in water at 1 mg/mI.
d) Ligation of stochastic genes to the vector Equimolar quantities of vector and polymers are mixed and incubated in the presence of 1000 un i ts of T4 DNA I igase, 1 mM
ATP, 10% polyethylene glycol, in the appropriate buffer, for 12 hours at 13 C. This step ligates the stochastic polymers in the expression vector and forms double stranded circular molecules which are, therefore, capable of transforming.
Transformaticn of competent clones.
Transformation of competent clones is carried out in the manner previously described.
III) Assembly of stochastic genes starting from a group of heptamers.
This procedure differs from that just discus$ea in that it utilizes palindromic heptamers have variable cohesive ends, In place of the octamers. This has the advantage of allowing assembly of stochastic sequences containing a smaller number of identical mo1-ifs.
a) Choice of a group of heptamers It is possible, as, an example, to use the following three palindromic heptamers:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A,G,C or T and R = A or T, and where polymerization cannot generate any "stop" codons and forms triplets specifying all the amino acids.
Clearly it is possible to use other groups of heptamers fulfill ing these same conditions.
b) Polymerization - of a group of heptamers This polymerization is carried out exactly in the fashion described above fcr octamers.
c) Elimination of cohesive extremities The polymers thus obtained have one unpaired base on their two 5' extremities. Thus, It is necessary to add the complementary base to the corresponding 3' extremities. This is carried out as follows: 10 micrograms of the double stranded polymers are reacted with 1 0 un i ts of the Klenow enzyme, i n the presence of the four deoxynuc l eot i de- phosphates (200 mM) in a volume of 100 ul, at 4 C, for 60 minutes. The enzyme is inactivated by phenol chloroform extraction, and the polymers are cleansed of the residual free nucleotides by differential precipitation. The polymers are then ligated to the host plasmid (previously linearized and dephosphorylated) by following the procedures described above.
It is to be noted that the two last procedures which were described utilize palindromic octamers or heptamers which constitute specific sites of certain restriction enzymes. These sites are absent, for the most part, from the pUC8 expression vector. Thus, it is possible to augment considerably the complexity of an initial preparation of stochastic genes by proceeding In the following way: The plasmid DNA derived from the culture of 10 7 independent transformants obtained by one of the two last procedures described above, i s i so I ated. After th i s DNA
is purified, it Is partially digested by the CIa I restriction enzyme (procedure II) or by the Pst I restriction enzyme (procedure 111). After inactivation of the enzyme, the partially digested DNA is treated with T4 DNA I igase, which has the effect of creating a very large number of new sequences, whi l e conserving 1~4 1595 -1,-the fundamental properties of the initial sequences. This new ensemble of stochastic sequences can then be used to transform competent cells.
In addition, the stochastic genes cloned by procedures 11 and 111 can be excised intact from the pUC8 expression vector by utilizing restriction sites belonging to the cloning vector and not represented in the stochastic DNA sequences.
Recombination within the stochastic genes generated by the two procedures just described, which results from the internal homology due to the recurrent molecular motifs, is an important additional method to achieve in vivo mutagenesis of the coding sequences. This results in an augmentation of the number of new genes which can be examined.
Finally, for all the procedures to generate novel synthetic genes, it Is possible to use a number of common techniques to modify genes i n vivo or in v i tro, such as a change of reading frame, inversion of sequences with respect to their promoter, point mutations, or utilization of host cells expressing one or several suppressor tRNAs.
In considering the above description, It is clear that it is possible to construct, in vitro, an extremely large number ( for example greater than a billion) different genes, by enzymatic polymerization of nucleotides or of oligonucleotides. This polymerization is carried out in a stochastic manner, as determined by the respective concentrations of the nucleotides or oligonucleotides present in the reaction mixture.
As indicated above, two methods can be utiiized to clone such genes (or coding sequences): the polymerization can be carried out directly on a cloning expression vector, which was previously linearized; or it is possible to proceed sequentially to the polymerization then the ligation of the polymers to the expression v ector .
In the two cases, the next step is transformation or transfection of competent bacteriaf cells (or cells in culture) . This step const i tutes cl on i ng the stochast i c genes in I iv i ng cel i s where they are indefinitely propagated and expressed.
Clearly, in addition to the procedures which were described above, it is feasible to use all other methods which are appropriate for the synth esis of stochastic sequences. In particular, It is possible to carry out polymeriza tion, by biochemical means, of single stranded oligomers of DNA or RNA obtained by chemical synthesis, then treat these segments of DNA or RNA by establ i shed procedures to generate double stranded DNA (cDNA) in order to clone such genes.
Screening or selection of clones of transformed host cells The final step of the procedure according to the invention consists in examining the transformed or transfected cells by selection or screening, in order to isolate one or several cells whose transform i ng or transfecting DNA leads to the synthesis of a transcription product (RNA) or translation product (protein) having a desired property. These properties can be, for example, enzymatic, functional, or structural.
One of the most important aspects of the procedure, according to the invention, is that it permits the simultaneous screening or selection of an exploitable product (RNA or protein) and the gene which produces that product. In addition, the DNA synthesized and cloned as described, can be selected or screened in order to isolate sequences of DNA constituting products in themselves, having exploitable biochemical properties.
We shali now describe, as non-limitating examples, preferred procedures for screening or selection of clones of transformed cells such that the novel proteins are of interest from the point of view of industrial or medical applications.
One of these procedures rests on the idea of producing, or obtaining, polyclonai or monoclonal antibodies, by established techniques, directed against a protein or another type of mol ecu I e of biochemical or medical interest, where that molecule is, or has been rendered, immunogenic, and thereafter using these ant kodi es as probes to i dent i fy among the very large number of clones transformed by stochastic genes, those whose protein react with .. these antibodies.. This reaction is a re-sult of a structural (epitope) homology which exists between the polypeptide synthesized by the stochastic gene and the initial molecule. It is possible in this way to isolate numbers of novel proteins with molecular features similar to the epitopes or antigenic determinants on the initial molecule. Such novel proteins are candidates to simulate, stimulate, modulate, or block the effect of the initial molecule. It should be clear that this means of selection or screening can have very many pharmacologic and biomedical applications. As noted above, the peptides identified as having epitopes similar to the initial molecule of Interest can be improved by modifying the stochastic genes coding for the said i dent i f i ed prote i ns or pept i des, fol l owed by recloning and rescreening, or derivitization of those peptides themselves by known procedures.
Below we describe, as a non limiting example, this first mode of operation in a concrete case:
EGF, (epidermal growth factor) is a small protein present in the blood, whose role is to stimulate the growth of epithelial cells.
This effect is obtained by the interaction of EGF with a specific receptor situated in the membrane of epithelial cells. Prepare antibodies directed against EGF by injecting animals with EGF
coupled to KLH (keyhofe Iimpet hemocyanin) to augment the Immunogenecity of the EGF. The anti-EGF antibodies of the immunized animals are purified, for example, by passage over an affinity column, where the I igand is EGF or a synthetic peptide corresponding to a fragment of EGF. The purified anti-EGF
antibodies are then used as probes to screen a large number of bacterial clones lysed by chloroform and on a solid support. The anti-EGF antibodies bind those stochastic peptides or proteins whose epitopes resemble those of the initial antigen. The clones containing such peptides or proteins are shown by autoradiography after i ncubati on of the sol i d support with radioactive protein A, or after incubation with a radioactive anti-antibody antibody.
These steps identify those clones, each of which contains one protein (and its gene) reacting with the screening antibody. It is feasible to screen among a very large number of colonies of bacterial cells or viral plaques (for example, on the order of 1,000,000) and it is feasible to detect extremely small quantities, on the order of 1 nanogram, of protein product.
Thereafter, the i dentif ied clones are cu I tur ed and the proteins so detected are purified In conventional ways. These proteins are tested in vitro in cultures of epithel ial cells to determine if they i nhi bi t, - simulate, or modu I ate the effects of EGF on these cultures. Among the proteins so obtained, some may be utilized for the chemoihirageutic treatment of epitheliomes. The activities of the proteins thus obtained can be improved by mutation of the DNA coding for the proteins, in ways ana I ogous to those descr i bed above, or by derivitizing the proteins identified.
A vzr i ant of _th i s procedure cons i sts in puri fy i ng these stochast i c peptides, polypeptides or proteins, which have epitopes or molecular features causing them to be bound by antibodies against some antigens, for example antigens of a pathogen, and then utilizing the identified peptides as vaccines or more generally utilizing them to confer an immunity against a pathogenic agent or to exercise other effects on the immunological system, for example, to create a tolerance or diminish hypersensitivity with respect to a given antigen, in particular due to binding of these peptides, polypeptides or proteins with the antibodies directed against this antigen. It is clear that it Is possible to use such peptides, polypeptides or proteins In vitro as well as in vivo.
More precisely, in the ensemble of novel proteins which react with the antibodies against a given antigen X, each has at least one epitope in cormon with X, thus the ensemble has an ensemble of epitopes in common with X. This permits utilization of the ensemble or sub-ensemble as a vaccine to confer immunity against X. It i s, for example, easy to purify one or several of the capsid proteins of the hepatitis B virus. These proteins can then be injected into an animal, for example, a rabbit, and the antibodies corresponding to the initial antigen can be recovered by affinity column purification. These antibodies may be used, as described above, to identify clones producing at least one protein having an epitope resembling at least one of the epitopes of the Initial antigen. After purification, these proteins are used as antigens (either alone or In combination) with the aim of confering protection against hepatitis B. The final production of the vaccine does not require further access to the initial pathogenic agent. Nor is it required that the initial antigens derived from the hepatitis 8 virus be protein antigens, rather they mlght include Polysaccharide or other antigenic determinants.
Further, in favorable cases, no access to the.initial pathogen is needed, rather the high titre circulating antibodies against the pathogen derived from an animai or human exposed to the pathogen can be used as the initial step to screen for peptides bound by those high titre antibodies. Such high titre circulating antibodies can reach 1p to 10% of all circulating antibodies, hence tp - 10% of the stochastic peptides or polypeptides identified as crossreacting will have antigenic determinants similar to the (perhaps unknown) pathogen. This mixture of identified cross reacting peptides can be used as a vaccine. Or the subset of peptides cross reacting with the high titre antibody molecules can be selected by screening the set of cross reacting peptides with the serum, and identifying those peptides to which a high level of circulating antibody is present in the serum. This selected set of cross reactino peptides may then be used with the a i m of produc i ng a vacc i ne conf er i ng i mmun i ty, or as agents w i th other immuno-modifying actions.
Note that, during the description of the procedures above, a number of means to achieve selection or screening have been described. All these procedur.es may require the purification of a particular protein from a transformed clone. These protein purifications can be carried out by established procedures and utilize, in particular, the techniques of gel chromatography, by ion exchange, and by affinity chromatography. In addition, the proteins generated by the stochastic genes can have been cloned in the form of hybrid proteins having, for example, a sequence of the B - galactosidase enzyme which permits affinity chromatography against anti - B-galactosidase antibodies, and allows the subsequent cleavage of the hybrid part ( that is to say, allowing separation of the novel part and the bacterial part of the hybrid protein.
Below we describe the principles and procedures for selection of peptides or polypeptides and the corresponding genes, according to a second method of screening or selection based on the detection of the capacity of these peptides or polypeptides to catalyse a speci f ic reaction.
As an concrete and non Iimiting example, screening or selection in the particular case of proteins capable of catalysing the cleavage of lactose, normally a function fulfilled by the enzyme B-galactosidase (B-gal) will be described.
As noted above, the first step of the procedure consists in generating a very large ensemble of expression vectors, each express i ng a di st i nct novel protein. To be concrete, for example, choose the pUC8 expression vector with cloning of stochastic sequences of DNA In the Pst I restriction site. The plasmids thus obtained are then introduced In a clone of E coii from whose genome the natural gene for B-galactosidase, Z,and a second gene EBG , unrelated to the first but able to mutate towards B -gal function, have both been eliminated. Such host cells (Z-,EBG-) are not able by themselves to hydrolyse lactose, and as a consequence to use lactose as a carbon source for growth. This permits uti I ization of such host clones for screen i ng or seI ecti on for B-gal function.
A.':.cosi;venientbiological assay to analyse transformed E coll clones for those which have novel genes expressing a B gal functions consists in the culture of bacteria transformed as described In petri dishes containing X-gal in the medium. In this case, all bacterial colonies expressing a B gal function are visualized as blue colonies. By using such a biological assay, it is possible to detect even weak catalytic activity. The specific activity of characteristic enzymes ranges from 10 and 10,000 product molecules per second.
Supposing that a protein synthesized by a stochastic gene. has a weak specific acitivity, on the order of one molecule per 100 seconds, it remains possible to detect such catalytic activity.
In a petri dish containing X-gal in the medium, and in the presence of the non metabolizable inducer IPTG (isopropyl-D-thio galactoside) visualization of a blue region requires cleavage of about 1010 to 1011 molecules'of X gal per square millimeter. A
bacterial colony expressing a weak enzyme and occupying a surface area of 1n,m2. has about 107 to 108 cells. If each cell has only one copy of the weak enzyme, each cell would need to catalyse cleavage of between 10,000 and 100 of X gal to be detected, which would require beween 2.7 and 270 hours. Since under selective conditions it is possible to am plify the number of copies of each plasmid per cell to 5 to 20 copies per cell, or even to 100 or 1000, and because up to 10% of the protein of the cell can be specified by the new gene, the duration needed to detect a colony b I ue in the case of 100 enzyme mol ecu 1 es of weak act i v i ty per ce I I
is on the order of 0.27 to 2.7 hours.
As a consequence of these facts, screening a very large number of independent bacterial colonies, each expressing a different novel gene, and using the capacity to express a B gal function as the selection criterion, is fully feasible. It is possible to carry out screening of about 2000 colonies in one Petri dish of 10 cm diameter. Thus, about 20 miliion colonies can be screened on a sheet of X gal agar 1 square meter.
It is important to note that bacterial colonies which appear blue on X gal Petri dishes might be false positives due to a mutation in the bacterial genome which confers on It the capacity to metabol ise lactose, or fer other reasons than those which result fran a catalytic activity of the novel protein expressed by the cells of the colony. Such false positives can be directly eliminated by purifying the DNA of the expression vector from the positive colony, and retransforming Z-, EBG- E coli host cells.
If the B gal activity is due to the novel protein coded by the new gene in the expression vector, all those cells transformed by that vector will exhibit B gal function. In contrast, if the initial blue colony Is due to a mutation In the genome of the host cell, it is a rare event and independent of the transformation, thus the number of cel I s of the new clone of transformed E coil capable of expressing B gaI function will be small or zero.
The power of mass simultaneous purification of all the expression vectors from all the positive clones (blue) followed by retransformation of naive bacteria should be stressed. Suppose that the aim Is to carry out a screening to select proteins having a catalytic function, and that the probability that a new peptide or polypeptide carries out this function at least weakly is 10-6 while the probability that a clone of the E coli bacterial host undergoes a mutation rendering it capable of carrying out the same function is 10`5 , then it can be calculated that among 20 million transformed bacteria which are screened, 20 positive clones will be attributable to the novel genes in expression vectors which each carries, while 200 positive clones will be the result of genomic mutation. Mass purification of the expression vectors from the total of 220 positiv e bacterial clones followed by retransformation of naive bacteria with the mixture of these express i on vectors w i l l produce a large number of pos i tive clones consisting of all those bacteria transformed with the 20 expression vectors which code for the novel proteins having the desired function and a very small number of bacterial clones resulting from genomic mutations and containing the 200 expression vectors which are not of interest. A small number of cycles of purification of expression vectors from positive bacterial colonies, followed by such retransformation, allows the detection of very rare expression vectors truely positive for a desired catalytic-ractivity despite a high background rate of mutations in the host cells for the same function.
Following screening operations of this type, it is possible to purify the new protein by established techniques. The production of that protein in large quantity is made possible by the fact that identification of the useful protein occurs together with slmuitaneous identificatlon of the gene coding for the same protein. Consequently, either the same expression vector can be used, or the novel gene can be transplanted into a more appropriate expression vector for its synthesis and isolation in large quantity.
It is feasible to apply this method of screening for any enzymatic function for which an appropriate biological assay exists. For such screenings, it is not necessary that the enzymatic function which is sought be useful to the host cell. It is possible to carry out screenings not only for enzymatic functions, but for any other desired property for which it Is possible to establish an appropriate biological assay. Further, it Is feasible to carry out, even In the simple case of B - gal function visualized on an X-gal Petri piate, a screening of on the order of 100 million, or even a billion novel genes for that cataiytic activity or other desired property.
Selection of transformed host cel i s.
On the other hand, It Is possible to use selection techniques for any property, catalytic or otherwise, where the presence or absence of the property can be rendered essential for the survival of the host cells containing the expression vectors which code for the novel genes, or also can be used to select for those viruses coding and expressing the desired novel gene. As a non-limiting, but concrete example, selection for B galastosidase function shall be described. An appropriate clone of Z-EBG- E. coli is not able to grow on lactose as the sole carbon source. Thus, after carrying out the first step described above, it is possible to culture a very large number of host cells transformed by the expression vectors coding for the novel genes, under selective conditions, either progressive diminution of other sources of carbon, or utilization of Iactose alone from the start. During the course of such selection, In vivo mutagenesis by recombination, or by explicitly recovering the expression vectors and mutagenizing their novel genes in vitro by various mutagens, or by any other common tech n i que, perm i ts adapt i ve improvements in the capacityto fulfil the desired catalytic function. When both selection techniques and convenient bioassay techniques exist at the same time, as in the present case, it is possible to use selection techniques initially to enrich the representation of host bacteria expressina the B - gal function, then carry out a screening on Petri-plateson X-gal medium to establish efficiently which are the positive cells. In the absence of convenient bieassays, appl ication of progressively stricter selection is the easiest route to purify one or a small number of distinct host cells whose expression vectors code for the proteins catalysing the desired reaction.
It is possible to utilize these techniques to find novel proteins having a large variety of structural and functional characteristics beyond the capacity to catalyse a specific reaction. For example, it is possible to carry out a screen or select for novel proteins which bind to ci s-regul atory sites on the DN A and thereby block the expression of one of the host cellI s functions, or block transcription of the DNA, stimulate transcription, etc.
For example, in the case of E. Coli, a clone mutant in the repressor of the lactose operon (I-) expresses B gal function constitutively due to the fact the lactose operator is not repressed. All cells of this type produce blue clones on Petri plates containing X-gal medium. It is possible to transform such host cells with expression vectors synthesizing novel proteins and carry out a screen on X-gal Petri plates in order to detect 1-hose clones which are not blue. Among those, some represent the case where the new protein binds to the lactose operator and represses the synthesis of B-gal. It is then feasible to mass isolate such plasmids, retransform, i- hosts isolate those clones which do not produce B-gal, and thereafter carry out a detailed verification.
As mentioned above, this procedure can be utilized in order to create then isolate, not only exploitable proteins, but also RNA
and DNA as products In themselves, having exploitable properties.
This results from the fact that, on one hand, the procedure consists in creating stochastic sequences of DNA which may interact directly with other cellular or biochemical constituents, and on the other hand, these sequences cloned In expression vectors are transcribed Into RNA which are themselves capable of multiple biochemical interactions.
-~ 8-An example of the use of the procedure to create and select for a DNA which is useful in itself.
This example illustrates selection for a useful DNA, and the purification and study of the mechanism of action of regulatory proteins which bind to the DNA. Consider a preparation of the oestradiol receptor, a protein obtained by standard techniques. In the presence of oestradiol, a steroid sexual hormone, the.
receptor changes conformation and binds tightly to certain specific sequences in the genomic DNA, thus affecting the transcription of genes implicated In sexual differentiation and the control of fertility. By incubating a mixture containing oestradiol, its receptor, and a large number of different stochastic DNA sequences inserted in their vectors, fol I owed by filtration of the mixture across a nitro cellulose membrane, one has a direct selection for those stochastic DNA sequences binding to the oestrogen-receptor complex, where only those DNAs bound to a protein are retained by the membrane. After washing and elution, the -DNA liberated from the membrane is utilized to transform bacteria. After culture of the transformed bacteria, the vectors which they contain are again purified and several cycles of i ncubat i on, f i I trat i on and transf ormat i on are carr i ed out as described above. These procedures allow the isolation of stochastic sequences of DNA having an elevated affinity for the oestradiol-receptor complex. Such sequences are open to numerous diagnostic and pharmacologic applications, in particular, for testing synthetic estrogens for the control of fertility and treatment of sterility.
Creation and selection of an RNA useful in Itself Let there be a large number of stochastic DNA sequences, produced as has been described and cloned in an expression vector. It follows that the RNA transcribed from these sequences in the transformed host cells can be useful products in themselves. As a non limiting example, it Is possible to select a stochastic gene coding for a suppressor transfer RNA (tRNA) by the following procedure:
A large number (> 103 ) of stochastic sequences are transformed into competent bacterial hosts carrying a "nonsense" mutation in the arg E. gene. These transformed bacteria are plated on minimal medium without argenine and with the selective antibiotic for that plasmid (ampicillin if the vector is pUC8). Only those transformed bacteria which have become capable of synthesizing arginine will be able to grow. This phenotype can result either f rom a back mutation of the host genome, or the presence i n the cell of a suppressor tRNA. It is easy to test each transformed colony to determine if the arg+ phenotype is or Is not due to the presence of the stochastic gene in Its vector; it suffices to purify the plasmid from this colony and verify that it confers an Arg+ phenotype on all arg E cells transformed by it.
Selection of proteins capable of catalysing a sequence of reactions.
Below we describe another means of selection, open to independent appi icati ons, based on the pri nci pl e of simultaneous and paral I el selection of a certain number of novel proteins capable of catalysing a connected sequence of reactions.
The basic idea of this method is the following: given an initial ensemble of chemical compounds considered as building blocks or elements of construction from which it is hoped to synthesize one or several desired chemical compounds by means of a catalysed sequence of chemical reactions, there exists a very large number of reaction routes which can be partially or completely substituted for one another, which are all thermodynamically possible, and which lead from the set of building blocks to the desired target compound(s). Efficient synthesis of the target compound is favored if each step of at least one react i on pathway leading from the building block compounds to the target compound is comprised of reactions each of which is catalysed. On tne other hand, it is relatively less important which among the many independent or partially Independent reaction pathways is catalysed. In the previous description, we have shown how it is poss i b l e to obta i n a very large number of host ce I I s each of wh i ch expresses a di st i nct novel protein.
Each of these novel proteins is a candidate to catalyse one or another of the possible reactions,in the set of all the possible reactions leading from the ensemble of building blocks to the target compoun d(s ) . I f a suf f i c i ent l y large number of stochast i c proteins is present in a reaction mixture containing the building b I ock compounds, such that a suf f i c i ent-l y large number of the possible reactions are catalysed, there is a high probability that one connected sequence of reactions leading from the set of building block compounds to the target compound will be catalysed by a subset of the novel proteins. It Is clear that this procedure can be extended to the catalysis not only of one, but of several target compounds simultaneously.
Based on this principle it is possible to proceed as follows in order to select in parallel a set of novel proteins catalysing a desired sequence of chemical reactions:
1. Specify the desired set of compounds constituting the building blocks, utilizing preferentially a reasonably large number of distinct chemical species in order to increase the number of potential concurrent reactions leading to the desired target compound(s).
2. Using an appropriate volume of reaction medium, add a very large number of novel stochastic proteins isolated from transformed or transfected cells synthesizing these proteins.
Carry out an assay to determine i f the target compound is formed.
If it is, confirm that this formation requires the presence of the mixture of novel proteins. If so, then then the mixture should contain a subset of proteins catalysing one or several reaction pathways leading from the building block set to the target compound. Purify and divide the initial ensemble of clones which synthesize the set of novel stochastic proteins. Thereafter, retest the subset to see If is able to catalyse the sequence of reactions leading to the target compound.
More precisely, as a non I imiti ng example, below we describe selection of a set of novel proteins capable of catalysing the synthesis of a specific small peptide, In particular, a pentapeptide, starting from a building block set constituted of smaller peptides and amino acids. All peptides are consistuted by a I inear sequence of 20 different types of amino acids oriented from the amino to the carboxy terminus. Any peptide can be formed in a single step by the terminal condensation of two smaller peptides (or of two amino acids), or by hydrolysis of a larger peptide. A peptide with M residues can thus be formed by M- 1 condensation reactions. The number of reactions, R, by which a set of peptides having lengths 1,2,3...M residues can be interconverted is larger than the number possible molecular species, T. This can be expressed as R/T = M - 2. Thus, starting from a given ensemble of peptides, a very large number of independent or partially independent reaction pathways lead to the synthesis of a specific target peptide. Choose a pentapeptide whose presence can be determined conveniently by some common assay technique for example HPLC (liquid phase high pressure chromatography), paper chromatcfgraphy,' etc. Formation of a peptide bond requires energy in a dilute aqueous medium, but if the peptides participating In the condensation reactions are adequately concentrated, formation of peptide bonds is thermodynamically favored over hydrolysis and occurs efficiently in the presence of an appropriate enzymatic catalyst, for example pepsin or trypsin, without requiring the presence of ATP or other high energy compounds. Such a reaction mixture of small peptides, whose amino acids are marked radioactively to act as tracters with 3H, 14C,35S, constituting the building block set can be used at suff icientlyhigh concentrations to lead to condensation reactions.
For example, it is feasible to proceed as follows: 15 mg of each amino acid and small peptides having 2 to 4 amino acids, chosen to constitute the building block set, are dissolved in a volume of 0.25m1 per 1.0 ml of a 0.1 M pH 7.6 phosphate buffer. A large number of novel proteins, generated and isolated as described above are purified from their bacterial other host cells. The mixture of novel proteins is dissolved to a final concentration on the order of 0.8 to 1.0 mg/mI in the same buffer. 0.25 ml to 0.5 ml of the protein mixture is added to the mixture of building blocks. This is incubated at 25"C to 40 C for 1 to 40 hours.
Al iquots of 8 ul are removed at regular i nterval s, the first i s used as a "blank" and taken before addition of the mixture of novel proteins. These aliquots are analysed by chromatography using n-butanol-acetic acid-pyridine-water (30:6:20:24) as the solvent. The chromatogram is dried, and analysed by ninhydrin or autoradlography (with or without intensifying screens). Because the compounds constituting the building block set are radioactively marked, the target compound w i I I be radioactive and It will have a specific activity high enough to permit detection ~341595 at the level of 1 - 10 ng. In place of standard chromatographic analysis, it is possible to use HPLC (high pressure liquid chromatography) which is faster and simpler to carry out. INore generally,all the usual analytic procedures can be employed.
Consequently it Is possible to detect a yield of the target compound(s) of less than one part per million by weight compared to the compounds used as Initial building blocks.
If the pentapeptide is formedin the conditions described above, but not when an extract is utilized which is derived from host cells transformed by an expression vector containing no stochastic genes, the formation of the pentapeptide is not the result of bacterial contaminants and thus requires the presence of a subset of the novel proteins in the reaction mixture.
The following step consists in the separation of the particular subset of cells which contain expression vectors with the novel proteins catalysing the sequence of reactions leading to the target pentapeptide. As an example, if the number of reactions forming this sequence is 5, there are about 5 novel proteins which catalyse the necessary reactions. If the clone bank of bacteria containing the expression vectors which code for the novel genes has a number of distinct novel genes which is on the order of 1,000,000, aiI these expression vectors are isolated en masse and retransformed into 100 distinct sets of 108 bacteria at a ratio of vectors to bacteria which is suff ici ently low that, on average, the number of bacteria in each set which are transformed is about half the number of initial genes, ie about 500,000.
Thus, the probability that any given one of the 100 sets of bacteria contains the entire set of 5 critical novel proteins Is (1/2)5 = 1/32. Among the 100 initial sets of bacteria, about 3 will contain the 5 critical transformants. In each of these sets, the total number of new genes Is only 500,000 rather than 1,000,000. By successive repetitions the total number of which is about 20 in the present case, this procedure isolates the 5 critical novel genes. Following this, mutagenesis and selection on this set of 5 stochastic genes allows improvement of the necessary catalytic functions. In a case where it is necessary to catalyse a sequence of 20 reactions, and 20 genes coding novel proteins need to be isolated in parallel, it suffic er, to adjust the mul ti pi icity of transformation such that each set of 108 bacteria receives 80% of the 10e6 stochastic genes, and to use 200 such sets of bacteria. The E robability that all 20 novel proteins are found in one set is 0.82 = 0.015. Thus, about 2 among the 200 sets will have the 20 novel genes which are needed to catalyse the formation of the target compound. The number of cycles required for i sol at i on of the 20 novel genes i s on the order of 30.
The principles and procedures described above generalize from the case of peptides to numerous areas of chemistry in which chemicai reactions take place in aqueous medium, In temperature, pH,and concentration conditions which permit general enzymatic function.
In each case it is necessary to make use of an assay method to detect the formation of the desired target compund(s). It is also necessary to chose a suf f i c i ent l y large number of bu i l d i ng b l ock compounds to augment the number of reaction sequences which lead to the tareget compound.
The concrete example which was given for the synthesis of a target pentapeptide can also be generalized as follows:
The procedure as described, generates among other products, stochastic peptides and proteins. These peptides or proteins can act, catalytically or in other ways, on other compounds. They can equally constitute the substrates on which they act. Thus, it is possible to select (or screen) for the capacity of such stochast i c pept i des or prote i ns to interact among themse I ves and thereby modify the conformation, the structure or the function of some among them. Similarly , it is possible to select (or screen) for the capacity of these peptides and proteins to catalyse among themselves, hydrolytic, condensation, transpeptidation or other reactions modifying the peptides. For example, the hydroiyisis of a g i ve stochast i c pept i de by at least one member of the set of stochast i c pept i des and prote i ns can be fol l owed and measured by radi cactive marking of the given protein fol l owed by an i ncubati on w i th a mix.ture-of the stochast i c prote i ns i n the presence of ions such as Mg,Ca,Zn, Fe and ATP or GTP. The appe-arance of radioactive fragments of the marked protein i s measured as described. The stochastic protein(s) which catalyse this reaction can aaain be isolated, along with the gene(s) producing them, by sequential diminution of the I ibrary of transformed clones, as described above.
An extension of the procedure consists in the selection of an ensemble of stochastic peptides and polypeptides capable of catalysing a'set of reactions leading from the initial building blocks (amino acids and small peptides) to some of the peptides or polypeptides of the set. It Is therefore also possible to select an ensemble capable of catalysing its own synthesis; such a ref l ex i veiy autocata lyt i c set can be estab l i shed i n a chemostat where the products of the reactions are constantly diluted, but where the concentration of the bu i I di ng blocks are mai ntai ned constant. Alternatively, synthesis of such a set is aided by encl os i ng the complex set of pept i des in t i posomes by standard techniques. In a hypertonic aqueous environment surrounding such I iposomes, condensation reactions formina larger peptides lowers the osmotic pressure inside the I iposomes, drives water molecules produced by the condensation reactions out of the Iiposomes, hence favors synthesis, of larger polymers. Existence of an autocatalytic ensemble can be verified by two dimensional gel electrophoresis and by HPLC, showing the synthesis of a stable distribution of peptides and polypeptides. The appropriate reaction volume depends on the number of molecular species used, and the concentrations necessary to favor the formation of peptide bonds over the i r hydrolys i s. The di str i but i on of mol ecu l ar species of an autocatalytic ensemble is free to vary or change due to the emergence of variant autocatalytic ensembles. The peptides arid polypeptides which constitute an autocataly tic set may have certain elements 1 n common with the large initial ensemble (consitituted of coded peptides and polypeptides as given by our procedure) but can also contain peptides and polypeptides which are not coded by the ensemble of stochastic genes coding for the Initial ensemble of peptides and proteins.
The set of stochastic genes whose products are necessary to establish such an autocatalytic set can be Isolated as has been described, by sequential diminution of the library of transformed clones. In addition, an autocatalytic set can contain coded peptioes initially coded by the stochastic genes and synthesized continuously in the autocatalytic set. To isolate this coded subset of peptides and proteins, the autocatalytic set can be used to obtain, through immunization in an animal, polyclonal sera recognizing a very large number of the constituents of the autocatalytic set.
These sera can be utilized to screen the library of stochastic genes to find those genQs expressing proteins able to combine with the antibodies present in the sera.
This set of stochastic genes expresses a large number of coded stochastic proteins which persist in the autocataly tic set. The remainder of the coded constituents of such an autocatalytic set can be isoiated by serial diminution of the Iibrary of stochastic genes, from which the subset detected by immunological methods has f i rst been subtracted.
Such autocatalytic sets of peptides and proteins, obtained as noted, may find a number of practical applications.
fragments thus obta i ned w i th T4 DNA I igase, i n such a manner to create a new ensemble of DNA containing new stochastic sequences, this new ensemble can therefore contain a number of stochastic genes larger than the number of genes in the initial ensemble.
One then utilizes this new ensemble of transforming DNA to transform the host cells and clone these genes, and finally utilizes screening and/ or selection and isolates the new clones of transformed host cells and finally these are cultivated to produce at least one pept i de or polypept i de, for example, a new protein, having a desired property.
Any other means to generate and clone stochastic DNA sequences so as to obtain their expression as novel peptides, polypeptides, or proteins, or their expression as the novel portion of a fusion protein, followed by screening or selection for a desired property and obtaining at least one clone producing a peptide with the desired property, can be used according to the Invention.
The property serving as the criterion for selection of the clones of host cells.can be the capacity of the peptides or polypeptides, produced by a given clone, to catalyse a given chemical reaction.
Further, for the production of several peptides and or polypeptides, the said property can be the capacity to catalyse a sequence of reactions leading from an initial group of chemical compounds to at least one target compound.
With the aim of producing an ensemble constituted by several or many peptides and or polypeptides which are reflexively autocatalytic, the said proprety can be the capacity to catalyse the synthesis of the same ensemble from amino acids and/ or ol igopeptides in an appropriate milieu.
The said property can also be the capacity to modify selectively the biological or chemical properties of a given compound, for example, the capacity to selectively modify the catalytic activity of a polypeptide.
The said property can also be the capacity to simulate, Inhibit, or modify at least one biological function of at least one biologically active compound, chosen, for example, among t;rE
hormones, neurotransmitters, adhesion factors, growth factors and specific regulators of DNA replication and/or transcription and/
or trans l at i on of RNA.
The said property can equally be the capacity of the peptide or polypeptide to bind to a given (igand.
-a- 4 1 5 9~-The Invention also has as its object the use of the peptide or polypeptide obtained by the procedures specified above, for the detection and/ or the titration of a ligand.
According to a particularly advantageous mode of utilization, the criterion for selection of the clones of transformed host cells is the capacity of these peptides or polypeptides to simulate or modify the effects of a biologically active molecule, for example, a protein; screening and/or selection for clones of transformed host cells producing at least one peptide or polypeptide having this property,is carried out by preparing or obtaining antibodies against the the active mol ecu I e, then uti I iz ing these antibodies after their purification, to identify the clones containing peptides or polypeptides which are bound by the said antibodies against the active molecule, then by cultivating the clones thus identified, separating and purifying the peptide or polypeptide produced by these clones, and finaliy by submitting the peptide or polypeptide to an in vitro assay to verify that it has the capacity to simulate or modify the effects of the said mol ecu I e.
The capacity to simulate or modify the effects of the said mol ecu i e by the stochast i c pept i de can be improved by modi f i cat i on of the gene coding for that peptide, retransformation of the host cells by the modified genes, and selection or screening for those modifications which improve the desired function. In addition, the said peptide can be modified chemicaliy, or derivatized, to improve its function.
According to this means to utilize the procedures according to the invention, the proper ty serving as the criterion of selection is that of havi ng at least one epitope s im i I ar to one of the epitopes of a given antigen.
The invention carries over to obtaining polypeptides by the procedure specified above and utilizable as chemotherapeutically active substances.
In particular, in the case where the said antigen is EGF, the invention permits obtaining polypeptides usable for chemotherapeutictreatment of epitheliomas.
The invention also appi ies to a use of the procedure specified above for the preparation of a vaccine; the application is characterized by the fact that antibodies against the pathogenic agent are i sol ated, for example anti bodi es formed after i njecti on of the pathogenic agent in the body of an animal capable of forminc antibodies against this agent, and these antibodies are used to identify the clones producing at least one protein having at least one epitope similar to one of the epitopes of the pathogenic agent, the transformed host cell corresponding to these clones are cultured to produce these proteins, this protein(s) is isolated and purified from the clones of cells, then this protein(s) is used for the production of a vaccine against the pathogenic agent. The identified proteins can, as above, be improved by modifications (eg. mutagenizing) of the stochastic genes coding for the said proteins, retransformation of those genes i nto appropriate host cei I s expressing the modi f ied 1341 a95 proteins, rescreening or selection of those with improved capacity to be bound by antibodies against the initial antigenic agent, and use of these improved proteins to produce a vaccine.
For example, in order to prepare an anti-HVB vaccine, one can extract and purify at least one capside protein of the HVB virus inject this protein into an animal capable of forming antibodies against this protein, recover and purify the antibodies thus formed, utilize these antibodies to identify the clones producing at least one protein having at least one epitope sim i I ar to one of the epitopes of the HVB virus, then cu l tivate the clones of transformed host cells corresponding to these clones in a manner to produce this protein(s), isolate and purify the protein(s) from the culture of these clones of cells and utilize the protein(s) for the production of an anti HVB vaccine.
According to a variant of the procedure, one identifies and isolates the clones of transformed host cells producing peptides or polypeptides having the property desired, by affinity chromatography against antibodies corresponding to a protein expressed by the natural part of the DNA hybrid.
For e;kample, in the case where the natural part of the hybrid DNA
contains a gene expressing B- galactosidase, one can advantageously Identify and isoiate the said clones of transformed host cells by affinity chromatography against anti B
galactosidase antibodies.
After expression and purification of hybrid peptides or polypeptides, one can separate and isolate their novel parts.
According to the invention, a means of utilizing the procedure is to screen or select for novel peptides polypeptides or proteins catalysing a given chemical reaction.
According to an advantageous means of utilizing the procedures according to the invention, the host cells consist in bacteria such as Escherichia coli whose genome contains neither the natural gene expressing B galactosidase, nor the EBG gene, that is to say, Z-,EBG- E coli. The tranformed cells are cultured in the presence of X gal and the indicator IPTG in the medium, and cells positive for B galactosidase functions are detected;
thereafter, the transforming DNA is transplanted into an appropriate clone of host cel I s for large scale culture to produce at least one peptide or polypeptide with B galactoasidase activity.
The property serving as the criterion for selection of the tranformed host cells can also be the capacity of the polypeptides or proteins produced by the culture of these clones to bind to a given compound.
This compound can be chosen advantagousely among peptides, polypeptides and proteins, notably among proteins regulating the transcription activity of DNA.
The invention has also as its object those proteins which are obtained in the case where the property serving as criterion of sel ecti on of the clones of transformed host cei 1 s consists in the capacity of these proteins to bind to regulatory proteins controlling transcription activity or replication of the DNA.
On the other hand, the said compound which is bound can also be chosen among DNA and RNA sequences.
The invention has,in addition, as an object obtaining a protein which is able to bind to DNA sequences which act as cis regulatory sequences controlling replication or transcription of neighboring DNA sequences, and by binding modify the transcription or replication of the neighboring DNA sequence. Equally the invention has as an object obtaining a protein which is able to bind to an RNA sequence and thereby control translation from that RNA or the stabiIity of the RNA.
The aim of the invention includes utilization of proteins obtained in the second case mentioned to modify the properties of transcription or replication of a sequence of DNA, in a cell containing the sequence of DNA, and expressing this protein.
The invention has as its object as weli a procedure to produce DNA, characterized by simultaneous production in the same medium, of genes at least partialiy composed of stochastic synthetic polynucleotides, that the genes thus obtained are introduced into host cel I s to produce an ensemb l e of transformed host cel 1 s, that screening and/or selection on this ensemble is carried out to i dent i fy those host ce l l s conta i n i ng stochast i c sequences of DNA
having at least one desired property , and finally, that the DNA
from the clones of host cells thus identified is isolated. The properties of the identified DNA can be improved by modification of the stochastic genes, eg through a variety of mutagenesis procedures known in themselves or described below, recioning into an appropriate vector, transformation of appropriate host cells, foi 1 owed by screen i ng or se i ect i on for an improved level of the desired property.
The invention also has as its object a procedure to produce RNA, characterized by simultaneous production in the same medium, of genes at least *partially composed of stochastic synthetic polynucleotides, that the genes thus obtained are introduced into host cells to produce an ensemble of transformed host cells, that the host cells so produced are cultivated simultaneously, and screening and/or selection of this ensemble is carried out in a manner to identify those host cells containing stochastic sequences of RNA having at least one desired property, and that the RNA be Isolated from the host cells thus identified. As above, the properties of the RNA thus Isolated can be Improved by modification of the corresponding stochastic genes, retransformation and reselection or rescreening.
The said property can be, the capacity to bind to a given compound, which might be for example a peptide or polypeptide or protein, or also the capacity to catalyse a given chemical reaction, or the capacity to be a transfer RNA.
In one aspect, the present invention provides a procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.
In another aspect, the present invention provides a method of detecting or titrating a ligand, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells: (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides: (d) screening said population of peptides or polypeptides for capacity to bind to a ligand; (e) contacting said peptide or polypeptide identified in step (d) with a sample suspected of containing said ligand. and (f) determining binding of said peptide or polypeptide to said ligand, wherein binding indicates the presence or amount of said ligand in said sample.
In yet another aspect, the present invention provides a method of inducing pharmacologic or chemotherapeutic action, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to selectively modify a chemical or biological property of a compound, and (e) contacting said peptide or polypeptide identified in step (d) with a sample suspected of containing said compound under conditions sufficient to selectively modify the chemical or biological effects of said compound.
In still yet another aspect, the present invention provides a method of diminishing the in vitro or in vivo concentration of antibodies specific for an antigen, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides: (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially ~-.
7a- 1341595 stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for at least one epitope similar to an epitope of an antigen, and (e) contacting said peptide or polypeptide identified in step (d) with a sample containing antibodies specific for said antigen under conditions sufficient for selective binding of said peptide or polypeptide and said antibodies.
In still yet another aspect, the present invention provides a method of preparing an agent for suppression of immunological hypersensitivity, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to selectively modify a chemical or biological property of a compound or for containing at least one epitope similar to an epitope of an antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having immunological hypersensitivity suppression activity.
In still yet another aspect, the present invention provides a method of preparing an agent for inducing tolerance, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides;
(b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for containing at least one epitope similar to an epitope of an antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having tolerance inducing activity.
In still yet another aspect, the present invention provides a method of preparing an agent for chemotherapeutic treatment of epitheliomas, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for at least one epitope similar to an epitope of an EGF antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having chemotherapeutic action against epitheliomas.
In still yet another aspect, the present invention provides a method of producing a selective binding peptide, polypeptide, protein, DNA or RNA
composition, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said ;,,.,' 7b- 13415 95 population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to bind to a compound, said compound comprising peptide, polypeptide, protein, DNA or RNA, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium.
In still yet another aspect, the present invention provides a procedure to produce DNA characterized by the fact that, in the same milieu, genes which are at least partially composed of stochastic synthetic polynucleotides are produced, that the genes so produced are introduced into host cells in a manner to produce an ensemble of transformed host cells, that these are grown so as to produce independent clones of the host cells so produced, that screening and/or selection is carried out on this ensemble to identify those host cells which contain those stochastic sequences of DNA having at least one desired property, and that such DNA is isolated from the identified cultures of the host cells.
In still yet another aspect, the present invention provides a method of modulating replication or transcription activity of a polynucleotide, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) culturing said host cells to produce independent clones containing said at least partially stochastic synthetic polynucleotides; (d) screening said at least partially stochastic synthetic polynucleotides for capacity to bind to a peptide, polypeptide or protein regulating transcription or replication of DNA, and (e) linking said at least partially stochastic synthetic polynucleotide identified in step (d) with a sequence of DNA, wherein said at least partially stochastic synthetic polynucleotide provides a cis-regulatory sequence having the capacity to modulate transcription or replication of said DNA.
In still yet another aspect, the present invention provides a method of modulating the activity of a cis-regulatory sequence of replication or transcription, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides: (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) culturing said host cells to produce independent clones containing said at least partially stochastic synthetic polynucleotides; (d) screening said at least partially stochastic synthetic polynucleotides for capacity to bind to a peptide, polypeptide or protein regulating transcription or replication of DNA, and (e) contacting said at least partially stochastic synthetic polynucleotides identified in step (d) with a sample containing said peptide, polypeptide or protein regulating transcription or replication of DNA
under conditions sufficient for selective binding, wherein said , ~õ.s 7c- 13-41595 selective binding of said at least partially stochastic synthetic polynucleotide modulates the transcription or replication activity of said peptide, polypeptide or protein.
In still yet another aspect, the present invention provides a procedure for the production of RNA, characterized by the fact that, in the same milieu, genes which are at least partially composed of synthetic stochastic polynucleotides are produced simultaneously, that the genes thus obtained are introduced in host cel l s in a manner to produce a n ensemble of transformed host cells, that the independent clones of transformed host cells so produced are grown simultaneously, that a screening and/or selection is carried out on this ensemble in a manner to identify those host cells which containing stochastic sequences of RNA having at least one desired property, and that the RNA is isolated from the cultures of host cells so identified.
First, we shall describe particularly useful procedures to carry out the synthesis of stochastic genes, and the introduction of those genes in bacteria to produce clones of transformed bacteria.
1) Direct synthesis on an expression vector.
a) Linearization of the vector.
30 micrograms, that is, approximately 1013 molecules of the pUC8 expression vector are linearized by incubation for 2 hours at 37 C with 100 units of the Pstl restriction enzyme in a volume of 300u1 of standard buffer for that enzyme. The linearized vector is treated with phenol-chloroform then precipitate in ethanol, taken up in a volume of 30 ul and loaded onto a 0.8% agarose gel in standard TEB buffer. After migration in a field of 3V/cm for three hours, the linearized vector is electro-eluted, precipitated in ethanol, and taken up in 30 ul of water.
b) Stochastic synthesis using the enzyme Terminal Transferase (TdT).
30 ug of the linearized vector are reacted with 30 units of TdT in 300 ul of the appropriate buffer, in the presence of 1mM dGTP, 1mM dCTP, 0.3 mM dTTP and 1 mM dATP. The lower concentration of dTTP is chosen in order to reduce the frequency of "stop" codons in the corresponding messenger RNA. A similar result, although somewhat less favorable, can be obtained by utilizing a lower concentration for dATP than for the other desoxynucleotide triphosphates. The progress of the polymerization on the 3' extremities of the Pstl sites is followed by analysis on a gel of aliquots taken during the course of the reaction.
When the reaction attains or passes a mean value of 300 nucleotides added per 3' extremity, it is stopped and the free nucleotides are separated from the polymer by differential precipitation or by passage over a column containing a molecular sieve such as Biogel*P60. After *Trade Mark :;ti T
7 d - 1 3 4 1 5 95 concentration by precipitation in ethanol, the polymers are subjected to a further polymerization with TdT, first in the presence of dATP, then in the presence of dTTP. These last two reactions are separated by a filtration on a gel and are carried out for short intervals (30 seconds to 3 minutes) in order to add sequentially 10-30 A followed by 10-30 T
to the 3' ends of the polymers.
c) Synthesis of the second strand of the stochastic DNA
Each molecule of vector possesses at the end of the preceeding operation, two stochastic sequences whose 3' ends are complementary.
The mixture of polymers is therefore incubated in conditions favoring hybridization of the complementary extremities st. ,~..
( 150mh1 NaCi , 10mM Tr i s-HCI , pH 7.6, 1 mN1 EDTA at 65 -C for 10 minutes, followed by lowering the temperature to 22 C at a rate of 3 to 4 C Per hour. The hybridized polymers are then reacted with 60 units of the large fragment (Kienow) of polymerase I, in the presence of the four nuc l eot i de tr i phosphates ( 200mh1) at 4 C for two hours. This step accomplishes the synthesis of the second strand from the 3' ends of the hybrid polymers. The molecules which result from this direct synthesis starting from linearized vector are thereafter utilized to transform competent cells.
d) Transformation of competent clones 100 to 200 ml of competent HB101 of C600 cells at a con.centration of 1010 cells/mi, are incubated with the stochastic DNA
preparation (from above) in the presence of 6mM CaC12, 6 mP-1 Tris-HCI pH8, 6 mP-i MgCl2 for 30 minutes at 0 C. A temperature shock of 3 minutes at 37 C is imposed on the mixture, followed by the addition of 400 to 800 ml of NZY culture medium, without ant i bi otics. The transformed cu l ture is Incubated at 37 C for 60 minutes, then diluted to 10 litres by addition of NZY medium containing 40 ug/ml of ampicillin. After 3 - 5' hours of incubation at 37 C, the amplified culture is centrifuged, and the pel I et of transformed cel I s i s lyophi lysed and stored at -70 C.
Such a culture contains 3 x 107' to 108, independent transformants, each containing a unique stochastic gene inserted into the expression vector.
II) Synthesis of stochastic genes starting from oligonucleotides w ithout cohesive ends.
This procedure is based on the fact that polymerization of judiciously chosen palindromic oligonucleotides permits construction of stochastic genes which have no "stop" codon in any of the six possible reading frames, whi l e at the same time assuring a balanced representation of triplets specifying all amino acids. Further, and to avoid a repetition of sequence motifs in the proteins which result while using only a small number of initial palindromic oligonucleotides, the oligonucleotides can contain a number of bases which is not a mul ti pi e of three. The example which fol I ows describes the use of one of the possible combinations which fulfil these criterio:
a) Choice of a group of octamers The group of oligonucleotides following:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' CCATATGG 3' 5' CATCGATG 3' Is composed of 5 paiindromes ( thus self complementary sequences) where it is easy to verify that their stochastic polymerization does not generate any "stop" codons, and specifies all the amino acids.
Obviously, one can utlIize other groups of palindromic octamers which do not generate any "stop" codons and specify all the amino acids found in polypeptides. Clearly, it is also possible to utilize non palindromic groups of octamers, or other oligomers, under the condition that their complements forming double stranded DNA are also used. Further it is possible to use more than 5 pal indromic octomers.
b) Assembly of an ensemble stochastic genes from a group of octamer s.
A mixture containing 5 ug of each of the oligonucleotides indicated above ( previously phosphorylated at the 5' position by a standard procedure) are reacted in a 100 ul volume containing 1 mM ATP, 10% polyethYl enegiycol, and 100 un i ts of T4 DNA I igase in the appropriate buffer at 13 C for six hours. This step carries out the stochastic polymerization of the oligomers in the double stranded state and without cohesive ends. The resulting polymers are isolated by passage over a molecular sieve (Biogel P60) recovering those with 20 to 100 oiigomers. After concentration, th i s f ract i on is aga i n su bm i tte d to cata i y s i s of po l y mer i z at i on by T4 DNA I igase under the condi ti ons described above. Thereafter, as described above, those polymers which have assembled at least 100 oligomers are i soi ated.
c) Preparation of the host pl asmi d The pUC8 express i on vector is 1 i near i zed by the Smal enzyme in the appropriate buffer, as described 9.~ove. The vector linearized by SP4a I does not have cohesive ends. Thus the linearized vector is treated by calf intesting alkaline phosphatase (CIP) at a level of one unit per microgram of vector in the appropriate buffer, at 37 C for 30 minutes. The CIP enzyme is thereafter inactivated by two successive extractions with phenol-choloform. The linearized and dephosphorylated vector is precipitated in ethanol, then redissolved in water at 1 mg/mI.
d) Ligation of stochastic genes to the vector Equimolar quantities of vector and polymers are mixed and incubated in the presence of 1000 un i ts of T4 DNA I igase, 1 mM
ATP, 10% polyethylene glycol, in the appropriate buffer, for 12 hours at 13 C. This step ligates the stochastic polymers in the expression vector and forms double stranded circular molecules which are, therefore, capable of transforming.
Transformaticn of competent clones.
Transformation of competent clones is carried out in the manner previously described.
III) Assembly of stochastic genes starting from a group of heptamers.
This procedure differs from that just discus$ea in that it utilizes palindromic heptamers have variable cohesive ends, In place of the octamers. This has the advantage of allowing assembly of stochastic sequences containing a smaller number of identical mo1-ifs.
a) Choice of a group of heptamers It is possible, as, an example, to use the following three palindromic heptamers:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A,G,C or T and R = A or T, and where polymerization cannot generate any "stop" codons and forms triplets specifying all the amino acids.
Clearly it is possible to use other groups of heptamers fulfill ing these same conditions.
b) Polymerization - of a group of heptamers This polymerization is carried out exactly in the fashion described above fcr octamers.
c) Elimination of cohesive extremities The polymers thus obtained have one unpaired base on their two 5' extremities. Thus, It is necessary to add the complementary base to the corresponding 3' extremities. This is carried out as follows: 10 micrograms of the double stranded polymers are reacted with 1 0 un i ts of the Klenow enzyme, i n the presence of the four deoxynuc l eot i de- phosphates (200 mM) in a volume of 100 ul, at 4 C, for 60 minutes. The enzyme is inactivated by phenol chloroform extraction, and the polymers are cleansed of the residual free nucleotides by differential precipitation. The polymers are then ligated to the host plasmid (previously linearized and dephosphorylated) by following the procedures described above.
It is to be noted that the two last procedures which were described utilize palindromic octamers or heptamers which constitute specific sites of certain restriction enzymes. These sites are absent, for the most part, from the pUC8 expression vector. Thus, it is possible to augment considerably the complexity of an initial preparation of stochastic genes by proceeding In the following way: The plasmid DNA derived from the culture of 10 7 independent transformants obtained by one of the two last procedures described above, i s i so I ated. After th i s DNA
is purified, it Is partially digested by the CIa I restriction enzyme (procedure II) or by the Pst I restriction enzyme (procedure 111). After inactivation of the enzyme, the partially digested DNA is treated with T4 DNA I igase, which has the effect of creating a very large number of new sequences, whi l e conserving 1~4 1595 -1,-the fundamental properties of the initial sequences. This new ensemble of stochastic sequences can then be used to transform competent cells.
In addition, the stochastic genes cloned by procedures 11 and 111 can be excised intact from the pUC8 expression vector by utilizing restriction sites belonging to the cloning vector and not represented in the stochastic DNA sequences.
Recombination within the stochastic genes generated by the two procedures just described, which results from the internal homology due to the recurrent molecular motifs, is an important additional method to achieve in vivo mutagenesis of the coding sequences. This results in an augmentation of the number of new genes which can be examined.
Finally, for all the procedures to generate novel synthetic genes, it Is possible to use a number of common techniques to modify genes i n vivo or in v i tro, such as a change of reading frame, inversion of sequences with respect to their promoter, point mutations, or utilization of host cells expressing one or several suppressor tRNAs.
In considering the above description, It is clear that it is possible to construct, in vitro, an extremely large number ( for example greater than a billion) different genes, by enzymatic polymerization of nucleotides or of oligonucleotides. This polymerization is carried out in a stochastic manner, as determined by the respective concentrations of the nucleotides or oligonucleotides present in the reaction mixture.
As indicated above, two methods can be utiiized to clone such genes (or coding sequences): the polymerization can be carried out directly on a cloning expression vector, which was previously linearized; or it is possible to proceed sequentially to the polymerization then the ligation of the polymers to the expression v ector .
In the two cases, the next step is transformation or transfection of competent bacteriaf cells (or cells in culture) . This step const i tutes cl on i ng the stochast i c genes in I iv i ng cel i s where they are indefinitely propagated and expressed.
Clearly, in addition to the procedures which were described above, it is feasible to use all other methods which are appropriate for the synth esis of stochastic sequences. In particular, It is possible to carry out polymeriza tion, by biochemical means, of single stranded oligomers of DNA or RNA obtained by chemical synthesis, then treat these segments of DNA or RNA by establ i shed procedures to generate double stranded DNA (cDNA) in order to clone such genes.
Screening or selection of clones of transformed host cells The final step of the procedure according to the invention consists in examining the transformed or transfected cells by selection or screening, in order to isolate one or several cells whose transform i ng or transfecting DNA leads to the synthesis of a transcription product (RNA) or translation product (protein) having a desired property. These properties can be, for example, enzymatic, functional, or structural.
One of the most important aspects of the procedure, according to the invention, is that it permits the simultaneous screening or selection of an exploitable product (RNA or protein) and the gene which produces that product. In addition, the DNA synthesized and cloned as described, can be selected or screened in order to isolate sequences of DNA constituting products in themselves, having exploitable biochemical properties.
We shali now describe, as non-limitating examples, preferred procedures for screening or selection of clones of transformed cells such that the novel proteins are of interest from the point of view of industrial or medical applications.
One of these procedures rests on the idea of producing, or obtaining, polyclonai or monoclonal antibodies, by established techniques, directed against a protein or another type of mol ecu I e of biochemical or medical interest, where that molecule is, or has been rendered, immunogenic, and thereafter using these ant kodi es as probes to i dent i fy among the very large number of clones transformed by stochastic genes, those whose protein react with .. these antibodies.. This reaction is a re-sult of a structural (epitope) homology which exists between the polypeptide synthesized by the stochastic gene and the initial molecule. It is possible in this way to isolate numbers of novel proteins with molecular features similar to the epitopes or antigenic determinants on the initial molecule. Such novel proteins are candidates to simulate, stimulate, modulate, or block the effect of the initial molecule. It should be clear that this means of selection or screening can have very many pharmacologic and biomedical applications. As noted above, the peptides identified as having epitopes similar to the initial molecule of Interest can be improved by modifying the stochastic genes coding for the said i dent i f i ed prote i ns or pept i des, fol l owed by recloning and rescreening, or derivitization of those peptides themselves by known procedures.
Below we describe, as a non limiting example, this first mode of operation in a concrete case:
EGF, (epidermal growth factor) is a small protein present in the blood, whose role is to stimulate the growth of epithelial cells.
This effect is obtained by the interaction of EGF with a specific receptor situated in the membrane of epithelial cells. Prepare antibodies directed against EGF by injecting animals with EGF
coupled to KLH (keyhofe Iimpet hemocyanin) to augment the Immunogenecity of the EGF. The anti-EGF antibodies of the immunized animals are purified, for example, by passage over an affinity column, where the I igand is EGF or a synthetic peptide corresponding to a fragment of EGF. The purified anti-EGF
antibodies are then used as probes to screen a large number of bacterial clones lysed by chloroform and on a solid support. The anti-EGF antibodies bind those stochastic peptides or proteins whose epitopes resemble those of the initial antigen. The clones containing such peptides or proteins are shown by autoradiography after i ncubati on of the sol i d support with radioactive protein A, or after incubation with a radioactive anti-antibody antibody.
These steps identify those clones, each of which contains one protein (and its gene) reacting with the screening antibody. It is feasible to screen among a very large number of colonies of bacterial cells or viral plaques (for example, on the order of 1,000,000) and it is feasible to detect extremely small quantities, on the order of 1 nanogram, of protein product.
Thereafter, the i dentif ied clones are cu I tur ed and the proteins so detected are purified In conventional ways. These proteins are tested in vitro in cultures of epithel ial cells to determine if they i nhi bi t, - simulate, or modu I ate the effects of EGF on these cultures. Among the proteins so obtained, some may be utilized for the chemoihirageutic treatment of epitheliomes. The activities of the proteins thus obtained can be improved by mutation of the DNA coding for the proteins, in ways ana I ogous to those descr i bed above, or by derivitizing the proteins identified.
A vzr i ant of _th i s procedure cons i sts in puri fy i ng these stochast i c peptides, polypeptides or proteins, which have epitopes or molecular features causing them to be bound by antibodies against some antigens, for example antigens of a pathogen, and then utilizing the identified peptides as vaccines or more generally utilizing them to confer an immunity against a pathogenic agent or to exercise other effects on the immunological system, for example, to create a tolerance or diminish hypersensitivity with respect to a given antigen, in particular due to binding of these peptides, polypeptides or proteins with the antibodies directed against this antigen. It is clear that it Is possible to use such peptides, polypeptides or proteins In vitro as well as in vivo.
More precisely, in the ensemble of novel proteins which react with the antibodies against a given antigen X, each has at least one epitope in cormon with X, thus the ensemble has an ensemble of epitopes in common with X. This permits utilization of the ensemble or sub-ensemble as a vaccine to confer immunity against X. It i s, for example, easy to purify one or several of the capsid proteins of the hepatitis B virus. These proteins can then be injected into an animal, for example, a rabbit, and the antibodies corresponding to the initial antigen can be recovered by affinity column purification. These antibodies may be used, as described above, to identify clones producing at least one protein having an epitope resembling at least one of the epitopes of the Initial antigen. After purification, these proteins are used as antigens (either alone or In combination) with the aim of confering protection against hepatitis B. The final production of the vaccine does not require further access to the initial pathogenic agent. Nor is it required that the initial antigens derived from the hepatitis 8 virus be protein antigens, rather they mlght include Polysaccharide or other antigenic determinants.
Further, in favorable cases, no access to the.initial pathogen is needed, rather the high titre circulating antibodies against the pathogen derived from an animai or human exposed to the pathogen can be used as the initial step to screen for peptides bound by those high titre antibodies. Such high titre circulating antibodies can reach 1p to 10% of all circulating antibodies, hence tp - 10% of the stochastic peptides or polypeptides identified as crossreacting will have antigenic determinants similar to the (perhaps unknown) pathogen. This mixture of identified cross reacting peptides can be used as a vaccine. Or the subset of peptides cross reacting with the high titre antibody molecules can be selected by screening the set of cross reacting peptides with the serum, and identifying those peptides to which a high level of circulating antibody is present in the serum. This selected set of cross reactino peptides may then be used with the a i m of produc i ng a vacc i ne conf er i ng i mmun i ty, or as agents w i th other immuno-modifying actions.
Note that, during the description of the procedures above, a number of means to achieve selection or screening have been described. All these procedur.es may require the purification of a particular protein from a transformed clone. These protein purifications can be carried out by established procedures and utilize, in particular, the techniques of gel chromatography, by ion exchange, and by affinity chromatography. In addition, the proteins generated by the stochastic genes can have been cloned in the form of hybrid proteins having, for example, a sequence of the B - galactosidase enzyme which permits affinity chromatography against anti - B-galactosidase antibodies, and allows the subsequent cleavage of the hybrid part ( that is to say, allowing separation of the novel part and the bacterial part of the hybrid protein.
Below we describe the principles and procedures for selection of peptides or polypeptides and the corresponding genes, according to a second method of screening or selection based on the detection of the capacity of these peptides or polypeptides to catalyse a speci f ic reaction.
As an concrete and non Iimiting example, screening or selection in the particular case of proteins capable of catalysing the cleavage of lactose, normally a function fulfilled by the enzyme B-galactosidase (B-gal) will be described.
As noted above, the first step of the procedure consists in generating a very large ensemble of expression vectors, each express i ng a di st i nct novel protein. To be concrete, for example, choose the pUC8 expression vector with cloning of stochastic sequences of DNA In the Pst I restriction site. The plasmids thus obtained are then introduced In a clone of E coii from whose genome the natural gene for B-galactosidase, Z,and a second gene EBG , unrelated to the first but able to mutate towards B -gal function, have both been eliminated. Such host cells (Z-,EBG-) are not able by themselves to hydrolyse lactose, and as a consequence to use lactose as a carbon source for growth. This permits uti I ization of such host clones for screen i ng or seI ecti on for B-gal function.
A.':.cosi;venientbiological assay to analyse transformed E coll clones for those which have novel genes expressing a B gal functions consists in the culture of bacteria transformed as described In petri dishes containing X-gal in the medium. In this case, all bacterial colonies expressing a B gal function are visualized as blue colonies. By using such a biological assay, it is possible to detect even weak catalytic activity. The specific activity of characteristic enzymes ranges from 10 and 10,000 product molecules per second.
Supposing that a protein synthesized by a stochastic gene. has a weak specific acitivity, on the order of one molecule per 100 seconds, it remains possible to detect such catalytic activity.
In a petri dish containing X-gal in the medium, and in the presence of the non metabolizable inducer IPTG (isopropyl-D-thio galactoside) visualization of a blue region requires cleavage of about 1010 to 1011 molecules'of X gal per square millimeter. A
bacterial colony expressing a weak enzyme and occupying a surface area of 1n,m2. has about 107 to 108 cells. If each cell has only one copy of the weak enzyme, each cell would need to catalyse cleavage of between 10,000 and 100 of X gal to be detected, which would require beween 2.7 and 270 hours. Since under selective conditions it is possible to am plify the number of copies of each plasmid per cell to 5 to 20 copies per cell, or even to 100 or 1000, and because up to 10% of the protein of the cell can be specified by the new gene, the duration needed to detect a colony b I ue in the case of 100 enzyme mol ecu 1 es of weak act i v i ty per ce I I
is on the order of 0.27 to 2.7 hours.
As a consequence of these facts, screening a very large number of independent bacterial colonies, each expressing a different novel gene, and using the capacity to express a B gal function as the selection criterion, is fully feasible. It is possible to carry out screening of about 2000 colonies in one Petri dish of 10 cm diameter. Thus, about 20 miliion colonies can be screened on a sheet of X gal agar 1 square meter.
It is important to note that bacterial colonies which appear blue on X gal Petri dishes might be false positives due to a mutation in the bacterial genome which confers on It the capacity to metabol ise lactose, or fer other reasons than those which result fran a catalytic activity of the novel protein expressed by the cells of the colony. Such false positives can be directly eliminated by purifying the DNA of the expression vector from the positive colony, and retransforming Z-, EBG- E coli host cells.
If the B gal activity is due to the novel protein coded by the new gene in the expression vector, all those cells transformed by that vector will exhibit B gal function. In contrast, if the initial blue colony Is due to a mutation In the genome of the host cell, it is a rare event and independent of the transformation, thus the number of cel I s of the new clone of transformed E coil capable of expressing B gaI function will be small or zero.
The power of mass simultaneous purification of all the expression vectors from all the positive clones (blue) followed by retransformation of naive bacteria should be stressed. Suppose that the aim Is to carry out a screening to select proteins having a catalytic function, and that the probability that a new peptide or polypeptide carries out this function at least weakly is 10-6 while the probability that a clone of the E coli bacterial host undergoes a mutation rendering it capable of carrying out the same function is 10`5 , then it can be calculated that among 20 million transformed bacteria which are screened, 20 positive clones will be attributable to the novel genes in expression vectors which each carries, while 200 positive clones will be the result of genomic mutation. Mass purification of the expression vectors from the total of 220 positiv e bacterial clones followed by retransformation of naive bacteria with the mixture of these express i on vectors w i l l produce a large number of pos i tive clones consisting of all those bacteria transformed with the 20 expression vectors which code for the novel proteins having the desired function and a very small number of bacterial clones resulting from genomic mutations and containing the 200 expression vectors which are not of interest. A small number of cycles of purification of expression vectors from positive bacterial colonies, followed by such retransformation, allows the detection of very rare expression vectors truely positive for a desired catalytic-ractivity despite a high background rate of mutations in the host cells for the same function.
Following screening operations of this type, it is possible to purify the new protein by established techniques. The production of that protein in large quantity is made possible by the fact that identification of the useful protein occurs together with slmuitaneous identificatlon of the gene coding for the same protein. Consequently, either the same expression vector can be used, or the novel gene can be transplanted into a more appropriate expression vector for its synthesis and isolation in large quantity.
It is feasible to apply this method of screening for any enzymatic function for which an appropriate biological assay exists. For such screenings, it is not necessary that the enzymatic function which is sought be useful to the host cell. It is possible to carry out screenings not only for enzymatic functions, but for any other desired property for which it Is possible to establish an appropriate biological assay. Further, it Is feasible to carry out, even In the simple case of B - gal function visualized on an X-gal Petri piate, a screening of on the order of 100 million, or even a billion novel genes for that cataiytic activity or other desired property.
Selection of transformed host cel i s.
On the other hand, It Is possible to use selection techniques for any property, catalytic or otherwise, where the presence or absence of the property can be rendered essential for the survival of the host cells containing the expression vectors which code for the novel genes, or also can be used to select for those viruses coding and expressing the desired novel gene. As a non-limiting, but concrete example, selection for B galastosidase function shall be described. An appropriate clone of Z-EBG- E. coli is not able to grow on lactose as the sole carbon source. Thus, after carrying out the first step described above, it is possible to culture a very large number of host cells transformed by the expression vectors coding for the novel genes, under selective conditions, either progressive diminution of other sources of carbon, or utilization of Iactose alone from the start. During the course of such selection, In vivo mutagenesis by recombination, or by explicitly recovering the expression vectors and mutagenizing their novel genes in vitro by various mutagens, or by any other common tech n i que, perm i ts adapt i ve improvements in the capacityto fulfil the desired catalytic function. When both selection techniques and convenient bioassay techniques exist at the same time, as in the present case, it is possible to use selection techniques initially to enrich the representation of host bacteria expressina the B - gal function, then carry out a screening on Petri-plateson X-gal medium to establish efficiently which are the positive cells. In the absence of convenient bieassays, appl ication of progressively stricter selection is the easiest route to purify one or a small number of distinct host cells whose expression vectors code for the proteins catalysing the desired reaction.
It is possible to utilize these techniques to find novel proteins having a large variety of structural and functional characteristics beyond the capacity to catalyse a specific reaction. For example, it is possible to carry out a screen or select for novel proteins which bind to ci s-regul atory sites on the DN A and thereby block the expression of one of the host cellI s functions, or block transcription of the DNA, stimulate transcription, etc.
For example, in the case of E. Coli, a clone mutant in the repressor of the lactose operon (I-) expresses B gal function constitutively due to the fact the lactose operator is not repressed. All cells of this type produce blue clones on Petri plates containing X-gal medium. It is possible to transform such host cells with expression vectors synthesizing novel proteins and carry out a screen on X-gal Petri plates in order to detect 1-hose clones which are not blue. Among those, some represent the case where the new protein binds to the lactose operator and represses the synthesis of B-gal. It is then feasible to mass isolate such plasmids, retransform, i- hosts isolate those clones which do not produce B-gal, and thereafter carry out a detailed verification.
As mentioned above, this procedure can be utilized in order to create then isolate, not only exploitable proteins, but also RNA
and DNA as products In themselves, having exploitable properties.
This results from the fact that, on one hand, the procedure consists in creating stochastic sequences of DNA which may interact directly with other cellular or biochemical constituents, and on the other hand, these sequences cloned In expression vectors are transcribed Into RNA which are themselves capable of multiple biochemical interactions.
-~ 8-An example of the use of the procedure to create and select for a DNA which is useful in itself.
This example illustrates selection for a useful DNA, and the purification and study of the mechanism of action of regulatory proteins which bind to the DNA. Consider a preparation of the oestradiol receptor, a protein obtained by standard techniques. In the presence of oestradiol, a steroid sexual hormone, the.
receptor changes conformation and binds tightly to certain specific sequences in the genomic DNA, thus affecting the transcription of genes implicated In sexual differentiation and the control of fertility. By incubating a mixture containing oestradiol, its receptor, and a large number of different stochastic DNA sequences inserted in their vectors, fol I owed by filtration of the mixture across a nitro cellulose membrane, one has a direct selection for those stochastic DNA sequences binding to the oestrogen-receptor complex, where only those DNAs bound to a protein are retained by the membrane. After washing and elution, the -DNA liberated from the membrane is utilized to transform bacteria. After culture of the transformed bacteria, the vectors which they contain are again purified and several cycles of i ncubat i on, f i I trat i on and transf ormat i on are carr i ed out as described above. These procedures allow the isolation of stochastic sequences of DNA having an elevated affinity for the oestradiol-receptor complex. Such sequences are open to numerous diagnostic and pharmacologic applications, in particular, for testing synthetic estrogens for the control of fertility and treatment of sterility.
Creation and selection of an RNA useful in Itself Let there be a large number of stochastic DNA sequences, produced as has been described and cloned in an expression vector. It follows that the RNA transcribed from these sequences in the transformed host cells can be useful products in themselves. As a non limiting example, it Is possible to select a stochastic gene coding for a suppressor transfer RNA (tRNA) by the following procedure:
A large number (> 103 ) of stochastic sequences are transformed into competent bacterial hosts carrying a "nonsense" mutation in the arg E. gene. These transformed bacteria are plated on minimal medium without argenine and with the selective antibiotic for that plasmid (ampicillin if the vector is pUC8). Only those transformed bacteria which have become capable of synthesizing arginine will be able to grow. This phenotype can result either f rom a back mutation of the host genome, or the presence i n the cell of a suppressor tRNA. It is easy to test each transformed colony to determine if the arg+ phenotype is or Is not due to the presence of the stochastic gene in Its vector; it suffices to purify the plasmid from this colony and verify that it confers an Arg+ phenotype on all arg E cells transformed by it.
Selection of proteins capable of catalysing a sequence of reactions.
Below we describe another means of selection, open to independent appi icati ons, based on the pri nci pl e of simultaneous and paral I el selection of a certain number of novel proteins capable of catalysing a connected sequence of reactions.
The basic idea of this method is the following: given an initial ensemble of chemical compounds considered as building blocks or elements of construction from which it is hoped to synthesize one or several desired chemical compounds by means of a catalysed sequence of chemical reactions, there exists a very large number of reaction routes which can be partially or completely substituted for one another, which are all thermodynamically possible, and which lead from the set of building blocks to the desired target compound(s). Efficient synthesis of the target compound is favored if each step of at least one react i on pathway leading from the building block compounds to the target compound is comprised of reactions each of which is catalysed. On tne other hand, it is relatively less important which among the many independent or partially Independent reaction pathways is catalysed. In the previous description, we have shown how it is poss i b l e to obta i n a very large number of host ce I I s each of wh i ch expresses a di st i nct novel protein.
Each of these novel proteins is a candidate to catalyse one or another of the possible reactions,in the set of all the possible reactions leading from the ensemble of building blocks to the target compoun d(s ) . I f a suf f i c i ent l y large number of stochast i c proteins is present in a reaction mixture containing the building b I ock compounds, such that a suf f i c i ent-l y large number of the possible reactions are catalysed, there is a high probability that one connected sequence of reactions leading from the set of building block compounds to the target compound will be catalysed by a subset of the novel proteins. It Is clear that this procedure can be extended to the catalysis not only of one, but of several target compounds simultaneously.
Based on this principle it is possible to proceed as follows in order to select in parallel a set of novel proteins catalysing a desired sequence of chemical reactions:
1. Specify the desired set of compounds constituting the building blocks, utilizing preferentially a reasonably large number of distinct chemical species in order to increase the number of potential concurrent reactions leading to the desired target compound(s).
2. Using an appropriate volume of reaction medium, add a very large number of novel stochastic proteins isolated from transformed or transfected cells synthesizing these proteins.
Carry out an assay to determine i f the target compound is formed.
If it is, confirm that this formation requires the presence of the mixture of novel proteins. If so, then then the mixture should contain a subset of proteins catalysing one or several reaction pathways leading from the building block set to the target compound. Purify and divide the initial ensemble of clones which synthesize the set of novel stochastic proteins. Thereafter, retest the subset to see If is able to catalyse the sequence of reactions leading to the target compound.
More precisely, as a non I imiti ng example, below we describe selection of a set of novel proteins capable of catalysing the synthesis of a specific small peptide, In particular, a pentapeptide, starting from a building block set constituted of smaller peptides and amino acids. All peptides are consistuted by a I inear sequence of 20 different types of amino acids oriented from the amino to the carboxy terminus. Any peptide can be formed in a single step by the terminal condensation of two smaller peptides (or of two amino acids), or by hydrolysis of a larger peptide. A peptide with M residues can thus be formed by M- 1 condensation reactions. The number of reactions, R, by which a set of peptides having lengths 1,2,3...M residues can be interconverted is larger than the number possible molecular species, T. This can be expressed as R/T = M - 2. Thus, starting from a given ensemble of peptides, a very large number of independent or partially independent reaction pathways lead to the synthesis of a specific target peptide. Choose a pentapeptide whose presence can be determined conveniently by some common assay technique for example HPLC (liquid phase high pressure chromatography), paper chromatcfgraphy,' etc. Formation of a peptide bond requires energy in a dilute aqueous medium, but if the peptides participating In the condensation reactions are adequately concentrated, formation of peptide bonds is thermodynamically favored over hydrolysis and occurs efficiently in the presence of an appropriate enzymatic catalyst, for example pepsin or trypsin, without requiring the presence of ATP or other high energy compounds. Such a reaction mixture of small peptides, whose amino acids are marked radioactively to act as tracters with 3H, 14C,35S, constituting the building block set can be used at suff icientlyhigh concentrations to lead to condensation reactions.
For example, it is feasible to proceed as follows: 15 mg of each amino acid and small peptides having 2 to 4 amino acids, chosen to constitute the building block set, are dissolved in a volume of 0.25m1 per 1.0 ml of a 0.1 M pH 7.6 phosphate buffer. A large number of novel proteins, generated and isolated as described above are purified from their bacterial other host cells. The mixture of novel proteins is dissolved to a final concentration on the order of 0.8 to 1.0 mg/mI in the same buffer. 0.25 ml to 0.5 ml of the protein mixture is added to the mixture of building blocks. This is incubated at 25"C to 40 C for 1 to 40 hours.
Al iquots of 8 ul are removed at regular i nterval s, the first i s used as a "blank" and taken before addition of the mixture of novel proteins. These aliquots are analysed by chromatography using n-butanol-acetic acid-pyridine-water (30:6:20:24) as the solvent. The chromatogram is dried, and analysed by ninhydrin or autoradlography (with or without intensifying screens). Because the compounds constituting the building block set are radioactively marked, the target compound w i I I be radioactive and It will have a specific activity high enough to permit detection ~341595 at the level of 1 - 10 ng. In place of standard chromatographic analysis, it is possible to use HPLC (high pressure liquid chromatography) which is faster and simpler to carry out. INore generally,all the usual analytic procedures can be employed.
Consequently it Is possible to detect a yield of the target compound(s) of less than one part per million by weight compared to the compounds used as Initial building blocks.
If the pentapeptide is formedin the conditions described above, but not when an extract is utilized which is derived from host cells transformed by an expression vector containing no stochastic genes, the formation of the pentapeptide is not the result of bacterial contaminants and thus requires the presence of a subset of the novel proteins in the reaction mixture.
The following step consists in the separation of the particular subset of cells which contain expression vectors with the novel proteins catalysing the sequence of reactions leading to the target pentapeptide. As an example, if the number of reactions forming this sequence is 5, there are about 5 novel proteins which catalyse the necessary reactions. If the clone bank of bacteria containing the expression vectors which code for the novel genes has a number of distinct novel genes which is on the order of 1,000,000, aiI these expression vectors are isolated en masse and retransformed into 100 distinct sets of 108 bacteria at a ratio of vectors to bacteria which is suff ici ently low that, on average, the number of bacteria in each set which are transformed is about half the number of initial genes, ie about 500,000.
Thus, the probability that any given one of the 100 sets of bacteria contains the entire set of 5 critical novel proteins Is (1/2)5 = 1/32. Among the 100 initial sets of bacteria, about 3 will contain the 5 critical transformants. In each of these sets, the total number of new genes Is only 500,000 rather than 1,000,000. By successive repetitions the total number of which is about 20 in the present case, this procedure isolates the 5 critical novel genes. Following this, mutagenesis and selection on this set of 5 stochastic genes allows improvement of the necessary catalytic functions. In a case where it is necessary to catalyse a sequence of 20 reactions, and 20 genes coding novel proteins need to be isolated in parallel, it suffic er, to adjust the mul ti pi icity of transformation such that each set of 108 bacteria receives 80% of the 10e6 stochastic genes, and to use 200 such sets of bacteria. The E robability that all 20 novel proteins are found in one set is 0.82 = 0.015. Thus, about 2 among the 200 sets will have the 20 novel genes which are needed to catalyse the formation of the target compound. The number of cycles required for i sol at i on of the 20 novel genes i s on the order of 30.
The principles and procedures described above generalize from the case of peptides to numerous areas of chemistry in which chemicai reactions take place in aqueous medium, In temperature, pH,and concentration conditions which permit general enzymatic function.
In each case it is necessary to make use of an assay method to detect the formation of the desired target compund(s). It is also necessary to chose a suf f i c i ent l y large number of bu i l d i ng b l ock compounds to augment the number of reaction sequences which lead to the tareget compound.
The concrete example which was given for the synthesis of a target pentapeptide can also be generalized as follows:
The procedure as described, generates among other products, stochastic peptides and proteins. These peptides or proteins can act, catalytically or in other ways, on other compounds. They can equally constitute the substrates on which they act. Thus, it is possible to select (or screen) for the capacity of such stochast i c pept i des or prote i ns to interact among themse I ves and thereby modify the conformation, the structure or the function of some among them. Similarly , it is possible to select (or screen) for the capacity of these peptides and proteins to catalyse among themselves, hydrolytic, condensation, transpeptidation or other reactions modifying the peptides. For example, the hydroiyisis of a g i ve stochast i c pept i de by at least one member of the set of stochast i c pept i des and prote i ns can be fol l owed and measured by radi cactive marking of the given protein fol l owed by an i ncubati on w i th a mix.ture-of the stochast i c prote i ns i n the presence of ions such as Mg,Ca,Zn, Fe and ATP or GTP. The appe-arance of radioactive fragments of the marked protein i s measured as described. The stochastic protein(s) which catalyse this reaction can aaain be isolated, along with the gene(s) producing them, by sequential diminution of the I ibrary of transformed clones, as described above.
An extension of the procedure consists in the selection of an ensemble of stochastic peptides and polypeptides capable of catalysing a'set of reactions leading from the initial building blocks (amino acids and small peptides) to some of the peptides or polypeptides of the set. It Is therefore also possible to select an ensemble capable of catalysing its own synthesis; such a ref l ex i veiy autocata lyt i c set can be estab l i shed i n a chemostat where the products of the reactions are constantly diluted, but where the concentration of the bu i I di ng blocks are mai ntai ned constant. Alternatively, synthesis of such a set is aided by encl os i ng the complex set of pept i des in t i posomes by standard techniques. In a hypertonic aqueous environment surrounding such I iposomes, condensation reactions formina larger peptides lowers the osmotic pressure inside the I iposomes, drives water molecules produced by the condensation reactions out of the Iiposomes, hence favors synthesis, of larger polymers. Existence of an autocatalytic ensemble can be verified by two dimensional gel electrophoresis and by HPLC, showing the synthesis of a stable distribution of peptides and polypeptides. The appropriate reaction volume depends on the number of molecular species used, and the concentrations necessary to favor the formation of peptide bonds over the i r hydrolys i s. The di str i but i on of mol ecu l ar species of an autocatalytic ensemble is free to vary or change due to the emergence of variant autocatalytic ensembles. The peptides arid polypeptides which constitute an autocataly tic set may have certain elements 1 n common with the large initial ensemble (consitituted of coded peptides and polypeptides as given by our procedure) but can also contain peptides and polypeptides which are not coded by the ensemble of stochastic genes coding for the Initial ensemble of peptides and proteins.
The set of stochastic genes whose products are necessary to establish such an autocatalytic set can be Isolated as has been described, by sequential diminution of the library of transformed clones. In addition, an autocatalytic set can contain coded peptioes initially coded by the stochastic genes and synthesized continuously in the autocatalytic set. To isolate this coded subset of peptides and proteins, the autocatalytic set can be used to obtain, through immunization in an animal, polyclonal sera recognizing a very large number of the constituents of the autocatalytic set.
These sera can be utilized to screen the library of stochastic genes to find those genQs expressing proteins able to combine with the antibodies present in the sera.
This set of stochastic genes expresses a large number of coded stochastic proteins which persist in the autocataly tic set. The remainder of the coded constituents of such an autocatalytic set can be isoiated by serial diminution of the Iibrary of stochastic genes, from which the subset detected by immunological methods has f i rst been subtracted.
Such autocatalytic sets of peptides and proteins, obtained as noted, may find a number of practical applications.
Claims (42)
1. Procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes, which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.
2. A procedure according to claim 1, characterized by the fact that these genes are produced by stochastic copolymerization of the four types of deoxyphosphonucleotides A, C, G, and T, starting from the two extremities of an expression vector which was previously linearized, then by formation of cohesive extremities in a manner to create a first strand of stochastic DNA constituted of a molecule of expression vector possessing two stochastic sequences whose 3' extremities are complementary, followed by synthesis of the second strand of the stochastic DNA.
3. A procedure according to claim 1, characterized by the fact that the genes are produced by stochastic copolymerization of double stranded oligonucleotides which do not have cohesive ends, in a manner so as to form fragments of stochastic DNA, followed by ligation of these fragments in an expression vector which was previously linearized.
4. A procedure according to claim 2 or 3, characterized by the fact that the expression vector is a plasmid.
5. A procedure according to claim 4, characterized by the fact that the expression vector is pUC8.
6. A procedure according to claim 2 or claim 3, characterized by the fact that the expression vector is a fragment of viral DNA.
7. A procedure according to claim 2 or claim 3, characterized by the fact that the expression vector is a hybrid of plasmid and viral DNA.
8. A procedure according to any one of claims 1 to 7 characterized by the fact that the host cells are prokaryotic cells.
9. A procedure according to any one of claims 1 to 7 characterized by the fact that the host cells are eukaryotic cells.
10. A procedure according to claim 8, characterized by the fact that the host cells are chosen among HB101 and C600.
11. A procedure according to claim 3, characterized by the fact that the oligonucleotides form a group of palindromic octamers.
12. A procedure according to claim 11, characterized by the fact that the group of palindromic octamers is the following group:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' CCATATGG 3' 5' CATCGATG 3'.
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' CCATATGG 3' 5' CATCGATG 3'.
13. A procedure according to claim 3, characterized by the fact that the oligonucleotides form a group of palindromic heptamers.
14. A procedure according to claim 13, characterized by the fact that the group of palindromic heptamers is the following group:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A, G, C, or T and R = A or T.
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A, G, C, or T and R = A or T.
15. A procedure according to claim 1, characterized by the fact that the said property is the capacity to catalyse a given chemical reaction.
16. A procedure according to claim 1 for the production of several peptides and/or polypeptides characterized by the fact that the said property is the capacity to catalyse a sequence of reactions leading from a given group of initial chemical compounds to at least one target compound.
17. A procedure according to claim 15 for the production of an ensemble consisting of more than one peptide and/or polypeptide which is reflexively autocatalytic, characterized by the fact that the said property is the capacity to catalyse the synthesis of the ensemble itself starting from amino acids and/or oligopeptides.
18. A procedure according to claim 1, characterized by the fact that the said property is the capacity to modify selectively the chemical and/or biological properties of a given compound.
19. A procedure according to claim 18, characterized by the fact that the said property is the capacity to modify selectively the catalytic activity of a polypeptide.
20. A procedure according to claim 18, characterized by the fact that the said property is the capacity to simulate or modify at least one biological function of at least one biologically active compound.
21. A procedure according to claim 20 characterized by the fact that the said biologically active compound is chosen among the hormones, neurotransmitters, adhesion or growth factors, and specific regulators of replication and/or transcription of DNA, and/or translation of RNA.
22. A procedure according to claim 1, characterized by the fact that the said property is the capacity to bind to a given ligand.
23. A procedure according to claim 1, characterized by the fact that the said property is to have at least one epitope similar to one of the epitopes of a given antigen.
24. A procedure according to claims 18 or 23, characterized by the fact that the said property is the capacity to simulate or modify the effects of a biologically active molecule, and that screening and/or selection of the clones of transformed host cells producing at least one peptide or polypeptide having this property is carried out by preparing or obtaining antibodies against said molecule, and utilizing these antibodies obtained to identify those clones containing those peptides or polypeptides bound by the antibodies, then by growing the clones thus identified and separating and purifying the peptide or polypeptide(s) produced by these clones, and finally by submitting these peptide(s) or polypeptide(s) to an assay in vitro to verify that said peptide(s) or polypeptide(s) have in fact the capacity to simulate or modify the effects of the said molecule wherein improvement in the capacity to simulate or modify the effects of the said molecule can be obtained by modification through mutation or otherwise of the stochastic genes coding for the identified peptides or polypeptides, followed by rescreening and retesting, or derivatization of those identified peptides or polypeptides by techniques known in themselves.
25. Procedure according to claim 23, characterized by the fact that the antigen is EGF.
26. A procedure according to claim 1, characterized by the fact that clones of transformed host cells producing peptides or polypeptides having the said property are identified and isolated by affinity chromatography on antibodies corresponding to a protein expressed by a natural fragment of a DNA hybrid.
27. A procedure according to claim 26, characterized by the fact that the natural fragment of the DNA hybrid contains a gene expressing .beta. galactosidase, and that one identifies and isolates the said clones of transformed cell hosts by affinity chromatography with anti .beta.
galactosidase antibodies.
galactosidase antibodies.
28. A procedure according to claim 1, characterized by the fact that the host cells consist in bacteria of Escherichia coli type, whose genome contains neither the natural .beta. galactosidase gene, nor the EBG gene. (Z-, EBG-E. coli), and that these transformed host cells are cultured in an X-gal medium also containing the inducer IPTG, that clones which are positive for .beta. galactosidase function are detected in the culture milieu, that thereafter the corresponding DNA is transplanted to a clone of host cells appropriate for industrial production of at least one peptide, polypeptide or protein with .beta.
galactosidase function.
galactosidase function.
29. A procedure according to claim 1, characterized by the fact that the said property is the capacity to bind to a given compound.
30. A procedure according to claim 29, characterized by the fact that the said compound is a peptide, polypeptide or protein.
31. A procedure according to claim 30, characterized by the fact that the said proteins are proteins regulating the transcription activity or replication of DNA.
32. A procedure according to claim 29, characterized by the fact that the said compound is a sequence of DNA or RNA.
33. A procedure to produce DNA characterized by the fact that, in the same milieu, genes which are at least partially composed of stochastic synthetic polynucleotide are produced, that the genes so produced are introduced into host cells in a manner to produce an ensemble of transformed host cells, that these are grown so as to produce independent clones of the host cells so produced, that screening and/or selection is carried out on this ensemble to identify those host cells which contain those stochastic sequences of DNA having at least one desired property, and that such DNA is isolated from the identified cultures of the host cells.
34. A procedure according to claim 33, characterized by the fact that the said property is the capacity to bind to a given compound.
35. A procedure according to claim 34, characterized by the fact that the said compound is a peptide, polypeptide or protein.
36. A procedure according to claim 34, characterized by the fact that the said compound is a compound regulating the transcription activity or the replication of DNA.
37. A procedure according to claim 36, characterized by the fact that the said compound is a regulatory protein controlling the transcription or replication of DNA.
38. A procedure according to claim 32, characterized by the fact that the proteins obtained have the capacity to modify the transcription activity, the replication, or the stability of DNA.
39. A procedure for the production of RNA, characterized by the fact that in the same milieu, genes which are at least partially composed of synthetic stochastic polynucleotides are produced simultaneously, that the genes thus obtained are introduced in host cells in a manner to produce an ensemble of transformed host cells, that the independent clones of transformed host cells so produced are grown simultaneously, that a screening and/or selection is carried out on this ensemble in a manner to identify those host cells which contain stochastic sequences of RNA having at least one desired property, and that the RNA is isolated from the cultures of host cells so identified.
40. A procedure according to claim 39, characterized by the fact that the said property is the capacity to bind to a given compound.
41. A procedure according to claim 39, characterized by the fact that the said property is the capacity to catalyse a given chemical reaction.
42. A procedure according to claim 39, characterized by the fact that the said property is to be a transfer RNA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH137985 | 1985-03-30 | ||
CH1379/85-8 | 1985-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1341595C true CA1341595C (en) | 2009-04-28 |
Family
ID=4209046
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000504653A Expired - Lifetime CA1339937C (en) | 1985-03-30 | 1986-03-20 | Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques |
CA000617095A Active CA1341595C (en) | 1985-03-30 | 1986-03-20 | Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000504653A Expired - Lifetime CA1339937C (en) | 1985-03-30 | 1986-03-20 | Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques |
Country Status (14)
Country | Link |
---|---|
US (7) | US5723323A (en) |
EP (3) | EP0590689B2 (en) |
JP (4) | JP2584613B2 (en) |
CN (1) | CN86102090A (en) |
AU (1) | AU4434585A (en) |
CA (2) | CA1339937C (en) |
CH (1) | CH0229046H1 (en) |
DE (7) | DE229046T1 (en) |
FR (1) | FR2579618B1 (en) |
GB (1) | GB2183661B (en) |
HK (1) | HK20292A (en) |
IN (2) | IN165561B (en) |
SG (1) | SG7992G (en) |
WO (1) | WO1986005803A1 (en) |
Families Citing this family (744)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866363A (en) | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US20060008806A1 (en) * | 1986-07-17 | 2006-01-12 | University Of Washington | Method for producing novel DNA sequence with biological activity |
US5824469A (en) * | 1986-07-17 | 1998-10-20 | University Of Washington | Method for producing novel DNA sequences with biological activity |
US5266684A (en) * | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2009996A1 (en) * | 1989-02-17 | 1990-08-17 | Kathleen S. Cook | Process for making genes encoding random polymers of amino acids |
US7413537B2 (en) | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
EP0494955B1 (en) * | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
CA2075974C (en) * | 1990-02-15 | 2001-02-06 | Dana M. Fowlkes | Totally synthetic affinity reagents |
US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5639595A (en) * | 1990-05-01 | 1997-06-17 | Isis Phamaceuticals, Inc. | Identification of novel drugs and reagents |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6569620B1 (en) | 1990-06-11 | 2003-05-27 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
US5962219A (en) * | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
US5837834A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
US5756287A (en) * | 1990-06-11 | 1998-05-26 | Nexstar Pharmaceuticals, Inc. | High affinity HIV integrase inhibitors |
US6232071B1 (en) | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US5789163A (en) * | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
US5668264A (en) * | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US6127119A (en) * | 1990-06-11 | 2000-10-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
EP1493825A3 (en) * | 1990-06-11 | 2005-02-09 | Gilead Sciences, Inc. | Method for producing nucleic acid ligands |
US5580737A (en) * | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
US5874218A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US6346611B1 (en) | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
US5637459A (en) * | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5683867A (en) * | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US6011020A (en) * | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US6030776A (en) * | 1990-06-11 | 2000-02-29 | Nexstar Pharmaceuticals, Inc. | Parallel SELEX |
US6177557B1 (en) | 1990-06-11 | 2001-01-23 | Nexstar Pharmaceuticals, Inc. | High affinity ligands of basic fibroblast growth factor and thrombin |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5688935A (en) * | 1990-06-11 | 1997-11-18 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
US5705337A (en) * | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
US5635615A (en) * | 1990-06-11 | 1997-06-03 | Nexstar Pharmaceuticals, Inc. | High affinity HIV nucleocapsid nucleic acid ligands |
US6331394B1 (en) | 1991-06-10 | 2001-12-18 | Gilead Sciences, Inc. | Nucleic acid ligands to integrins |
US6344321B1 (en) | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
US5503978A (en) * | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5527894A (en) * | 1990-06-11 | 1996-06-18 | Nexstar Pharmacueticals, Inc. | Ligands of HIV-1 tat protein |
US5707796A (en) * | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US5763173A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
US6124449A (en) * | 1990-06-11 | 2000-09-26 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
US5641629A (en) * | 1990-06-11 | 1997-06-24 | Nexstar Pharmacueticals Inc | Spectroscopically detectable nucleic acid ligands |
US6140490A (en) * | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5472841A (en) * | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
US5849890A (en) * | 1990-06-11 | 1998-12-15 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones |
US5780228A (en) * | 1990-06-11 | 1998-07-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6465189B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Systematic evolution of ligands by exponential enrichment: blended selex |
US20060084797A1 (en) * | 1990-06-11 | 2006-04-20 | Gilead Sciences, Inc. | High affinity TGFbeta nucleic acid ligands and inhibitors |
US5731144A (en) * | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
US5654151A (en) * | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
US5543293A (en) * | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
US5795721A (en) * | 1990-06-11 | 1998-08-18 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of ICP4 |
US6696252B2 (en) | 1990-06-11 | 2004-02-24 | Gilead Sciences, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6001988A (en) * | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US5726017A (en) * | 1990-06-11 | 1998-03-10 | Nexstar Pharmaceuticals, Inc. | High affinity HIV-1 gag nucleic acid ligands |
US5567588A (en) * | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5763566A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US5869641A (en) * | 1990-06-11 | 1999-02-09 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of CD4 |
US5972599A (en) * | 1990-06-11 | 1999-10-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
US5766853A (en) * | 1990-06-11 | 1998-06-16 | Nexstar Pharmaceuticals, Inc. | Method for identification of high affinity nucleic acid ligands to selectins |
US5864026A (en) * | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5789157A (en) * | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5874557A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
US5648214A (en) * | 1990-06-11 | 1997-07-15 | University Research Corporation | High-affinity oligonucleotide ligands to the tachykinin substance P |
US5731424A (en) * | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US5660985A (en) * | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US6716580B2 (en) | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
US6083696A (en) * | 1990-06-11 | 2000-07-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands exponential enrichment: blended selex |
US5637682A (en) * | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to the tachykinin substance P |
US6759392B1 (en) | 1990-06-11 | 2004-07-06 | Gilead Sciences, Inc. | High affinity RNA ligands of basic fibroblast growth factor |
US5750342A (en) * | 1990-06-11 | 1998-05-12 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
US5763177A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5587468A (en) * | 1990-06-11 | 1996-12-24 | University Research Corporation | High affinity nucleic acid ligands to HIV integrase |
US5837456A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones |
US5861254A (en) * | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
US5853984A (en) * | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
US5686592A (en) * | 1990-06-11 | 1997-11-11 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to immunoglobulin E (IgE) |
US5693502A (en) * | 1990-06-11 | 1997-12-02 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
US5846713A (en) * | 1990-06-11 | 1998-12-08 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US20040132067A1 (en) * | 1990-06-11 | 2004-07-08 | Somalogic, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US6465188B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US5629155A (en) * | 1990-06-11 | 1997-05-13 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to immunoglobulin E (IgE) |
US5723289A (en) * | 1990-06-11 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | Parallel selex |
US5712375A (en) * | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5674685A (en) * | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
DE69233697T2 (en) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Process for the development of binding microproteins |
US6028186A (en) * | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
US6762290B1 (en) * | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
WO1993003172A1 (en) * | 1991-08-01 | 1993-02-18 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
DK1024191T3 (en) * | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
US5656467A (en) * | 1992-01-09 | 1997-08-12 | The Trustees Of The University Of Pennsylvania | Methods and materials for producing gene libraries |
EP1477558A1 (en) * | 1992-03-16 | 2004-11-17 | WOHLSTADTER, Jacob Nathaniel | Selection methods |
US5869644A (en) * | 1992-04-15 | 1999-02-09 | The Johns Hopkins University | Synthesis of diverse and useful collections of oligonucleotidies |
US5719273A (en) * | 1993-06-14 | 1998-02-17 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide |
US5998142A (en) * | 1993-09-08 | 1999-12-07 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
WO1995010296A1 (en) * | 1993-10-12 | 1995-04-20 | Glycomed Incorporated | A library of glyco-peptides useful for identification of cell adhesion inhibitors |
US20060078561A1 (en) * | 1994-01-31 | 2006-04-13 | The Trustees Of Boston University | Polyclonal antibody libraries |
PT744958E (en) | 1994-01-31 | 2003-11-28 | Univ Boston | BANKS OF POLYCLONE ANTIBODIES |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US20060257890A1 (en) * | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US7153948B2 (en) | 1994-04-25 | 2006-12-26 | Gilead Sciences, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
US6048698A (en) * | 1994-09-20 | 2000-04-11 | Nexstar Pharmaceuticals, Inc. | Parallel SELEX™ |
JPH10506463A (en) * | 1994-09-21 | 1998-06-23 | サイトーゲン コーポレーション | Antigen-binding peptide (abtide) from peptide library |
US5885577A (en) * | 1994-09-21 | 1999-03-23 | Cytogen Corporation | Antigen binding peptides (abtides) from peptide libraries |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
ATE274520T1 (en) * | 1995-05-03 | 2004-09-15 | Gilead Sciences Inc | SYSTEMATIC EVOULTION OF LIGANDS THROUGH EXPONENTIAL ENHANCEMENT: TISSUE-SELEX |
US5859228A (en) * | 1995-05-04 | 1999-01-12 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US8071737B2 (en) | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US20010053523A1 (en) * | 1995-06-02 | 2001-12-20 | M&E Biotech A/S. | Method for identification of biologically active peptides and nucleic acids |
US5723594A (en) * | 1995-06-07 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US6207816B1 (en) | 1995-06-02 | 2001-03-27 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to growth factors |
US20090118481A1 (en) * | 1995-06-07 | 2009-05-07 | Gilead Sciences, Inc. | High Affinity Nucleic Acid Ligands To Lectins |
US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
US6475806B1 (en) | 1995-06-07 | 2002-11-05 | Praecis Pharmaceuticals, Inc. | Anchor libraries and identification of peptide binding sequences |
DE69638318D1 (en) * | 1995-06-07 | 2011-02-17 | Gilead Sciences Inc | Nucleic acid ligands that bind to and inhibit DNA polymerases |
US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
US5797870A (en) * | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
US6183967B1 (en) | 1995-06-07 | 2001-02-06 | Nexstar Pharmaceuticals | Nucleic acid ligand inhibitors to DNA polymerases |
US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
US7018793B1 (en) * | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US20020028443A1 (en) * | 1999-09-27 | 2002-03-07 | Jay M. Short | Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process |
US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6361974B1 (en) * | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6740506B2 (en) | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
US20020164580A1 (en) * | 1995-12-07 | 2002-11-07 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
US6939689B2 (en) | 1995-12-07 | 2005-09-06 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
AU725716C (en) | 1996-01-23 | 2003-02-20 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
US6365344B1 (en) | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6838238B1 (en) | 1996-10-17 | 2005-01-04 | Invitrogen Corporation | Morphatides: novel shape and structure libraries |
US6426335B1 (en) * | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
EP0948632A1 (en) | 1996-10-31 | 1999-10-13 | Smithkline Beecham Corporation | Methods for the characterization and selection of rna target motifs that bind compounds of pharmaceutical use |
US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
EP1007732B1 (en) | 1997-01-17 | 2006-07-26 | Maxygen, Inc. | EVOLUTION OF procaryotic WHOLE CELLS BY RECURSIVE SEQUENCE RECOMBINATION |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6261804B1 (en) * | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US8207093B2 (en) * | 1997-01-21 | 2012-06-26 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
ES2373110T3 (en) | 1997-01-21 | 2012-01-31 | The General Hospital Corporation | SELECTION OF PROTEINS USING ARN-PROTEIN FUSIONS. |
US5871924A (en) * | 1997-01-27 | 1999-02-16 | Nexstar Pharmaceuticals, Inc. | Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis |
US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US6180341B1 (en) | 1997-05-01 | 2001-01-30 | Board Of Regents, The Universiry Of Texas System | In vitro scanning saturation mutagenesis of proteins |
US6391547B1 (en) * | 1997-09-09 | 2002-05-21 | Center For The Application Of Molecular Biology To International Agriculture | Microbial β-glucuronidase genes, gene products and uses thereof |
US7087420B1 (en) | 1997-07-17 | 2006-08-08 | Cambia | Microbial β-glucuronidase genes, gene products and uses thereof |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
EP1690868A1 (en) | 1997-10-31 | 2006-08-16 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
AU746786B2 (en) * | 1997-12-08 | 2002-05-02 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
US20030219803A1 (en) * | 1997-12-15 | 2003-11-27 | Somalogic, Incorporated | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
US6261783B1 (en) | 1997-12-15 | 2001-07-17 | Gilead Sciences, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
US5989823A (en) * | 1998-09-18 | 1999-11-23 | Nexstar Pharmaceuticals, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
US20060057573A1 (en) | 2002-02-15 | 2006-03-16 | Somalogic, Inc | Methods and reagents for detecting target binding by nucleic acid ligands |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
FR2782325B1 (en) * | 1998-08-12 | 2002-05-24 | Proteus | METHOD OF IDENTIFYING POLYNUCLEOTIDE SEQUENCES AND / OR CORRESPONDING PROTEINS FROM A SAMPLE OF NUCLEIC ACIDS |
US7157083B2 (en) * | 1998-04-17 | 2007-01-02 | Surrogate Pharmaceutical Pathways, Llc | Compositions and methods for treating retroviral infections |
EP1073670A1 (en) | 1998-05-01 | 2001-02-07 | Maxygen, Inc. | Optimization of pest resistance genes using dna shuffling |
US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
CA2334170A1 (en) | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
DE69941193D1 (en) | 1998-08-17 | 2009-09-10 | Bristol Myers Squibb Co | IDENTIFICATION OF COMPOUND PROTEIN INTERACTIONS WITH LIBRARIES OF COUPLED PROTEIN NUCLEIC ACID MOLECULES |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
US6570003B1 (en) * | 2001-01-09 | 2003-05-27 | Lexion Genetics Incorporated | Human 7TM proteins and polynucleotides encoding the same |
DE60042730D1 (en) * | 1999-01-05 | 2009-09-24 | Univ Boston | IMPROVED CLONING PROCESS |
US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
WO2000042559A1 (en) * | 1999-01-18 | 2000-07-20 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US20030054360A1 (en) * | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
US20090130718A1 (en) * | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
US6329145B1 (en) | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
CA2362737A1 (en) | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
US6703240B1 (en) | 1999-04-13 | 2004-03-09 | Maxygar, Inc. | Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes |
US7332308B1 (en) | 1999-05-21 | 2008-02-19 | The Penn State Research Foundation | Incrementally truncated nucleic acids and methods of making same |
US6280943B1 (en) * | 1999-06-17 | 2001-08-28 | Gilead Sciences, Inc. | 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands |
EP1860188B1 (en) | 1999-07-07 | 2011-05-04 | ZymoGenetics, Inc. | Human cytokine receptor |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
US7005260B1 (en) | 2000-01-28 | 2006-02-28 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
ATE428719T1 (en) * | 1999-07-29 | 2009-05-15 | Gilead Sciences Inc | NUCLEIC ACID LIGANDS FOR HEPATOCYTIC GROWTH FACTOR/DISPERSION FACTOR (HGF/SF) AND ITS C-MET RECEPTOR |
US6171795B1 (en) | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
US6506887B1 (en) | 1999-07-29 | 2003-01-14 | Somalogic, Incorporated | Conditional-selex |
US6864079B2 (en) | 2001-04-06 | 2005-03-08 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6586230B1 (en) * | 2000-10-27 | 2003-07-01 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6841377B1 (en) * | 2001-06-13 | 2005-01-11 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6797510B1 (en) * | 2001-05-24 | 2004-09-28 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US20080050809A1 (en) * | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
US6777545B2 (en) * | 2001-04-06 | 2004-08-17 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US6541252B1 (en) | 2000-05-19 | 2003-04-01 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
AU784983B2 (en) * | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
WO2001053539A1 (en) | 2000-01-24 | 2001-07-26 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US7022479B2 (en) * | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US20020077464A1 (en) * | 2000-01-26 | 2002-06-20 | Turner C. Alexander | Novel human neurexin-like proteins and polynucleotides encoding the same |
US20050239061A1 (en) * | 2000-03-01 | 2005-10-27 | Marshall William S | Identification and use of effectors and allosteric molecules for the alteration of gene expression |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
WO2001075178A2 (en) * | 2000-04-04 | 2001-10-11 | Enanta Pharmaceuticals, Inc. | Methods for identifying peptide aptamers capable of altering a cell phenotype |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US20040029113A1 (en) * | 2000-04-17 | 2004-02-12 | Ladner Robert C. | Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins |
AU2001257091A1 (en) * | 2000-04-18 | 2001-10-30 | Gilead Sciences, Inc. | Aptamer based two-site binding assay |
US6479262B1 (en) | 2000-05-16 | 2002-11-12 | Hercules, Incorporated | Solid phase enzymatic assembly of polynucleotides |
AU2001274923A1 (en) * | 2000-05-23 | 2001-12-03 | Lexicon Genetics Incorporated | Novel human thrombospondin-like proteins and polynucleotides encoding the same |
WO2001094583A2 (en) * | 2000-06-07 | 2001-12-13 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
WO2001094417A2 (en) * | 2000-06-09 | 2001-12-13 | Lexicon Genetics Incorporated | Novel human seven transmembrane proteins and polynucleotides encoding the same |
US6465632B1 (en) * | 2000-06-09 | 2002-10-15 | Lexicon Genetics Incorporated | Human phosphatases and polynucleotides encoding the same |
EP2077279B1 (en) | 2000-06-28 | 2012-09-05 | Amgen Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
US6994963B1 (en) | 2000-07-10 | 2006-02-07 | Ambion, Inc. | Methods for recombinatorial nucleic acid synthesis |
WO2002006456A1 (en) * | 2000-07-13 | 2002-01-24 | Invitrogen Corporation | Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix |
US20030017552A1 (en) * | 2000-07-21 | 2003-01-23 | Jarrell Kevin A. | Modular vector systems |
WO2002010183A1 (en) * | 2000-07-31 | 2002-02-07 | Menzel, Rolf | Compositions and methods for directed gene assembly |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
CA2417240A1 (en) * | 2000-08-07 | 2002-02-14 | Sloan-Kettering Institute For Cancer Research | Method and composition for immunization using mixed pools of mutated nucleic acids or peptides |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
CA2420036A1 (en) * | 2000-08-22 | 2002-02-28 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding the same |
AU2001285326A1 (en) * | 2000-08-31 | 2002-03-13 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
EP2351855A1 (en) | 2000-09-26 | 2011-08-03 | Duke University | RNA aptamers and methods for identifying the same |
AU2002211624A1 (en) * | 2000-10-10 | 2002-04-22 | Genencor International, Inc. | Information rich libraries |
AU2002224401B2 (en) | 2000-10-16 | 2007-12-06 | Gilead Sciences, Inc. | Nucleic acid ligands to the prostate specific membrane antigen |
WO2002070705A2 (en) * | 2000-10-27 | 2002-09-12 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding them |
AU2002232936A1 (en) * | 2000-10-30 | 2002-05-15 | Lexicon Genetics Incorporated | Human 7TM proteins and polynucleotides encoding the same |
WO2002042438A2 (en) * | 2000-11-20 | 2002-05-30 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
AU2002220275A1 (en) * | 2000-12-08 | 2002-06-18 | The Board Of Trustees Of The University Of Illinois | Mutated class ii major histocompatibility proteins |
CA2431007A1 (en) | 2000-12-11 | 2002-07-18 | Lexicon Genetics Incorporated | Novel human kinase and polynucleotides encoding the same |
AU3264202A (en) * | 2000-12-12 | 2002-06-24 | Lexicon Genetics Inc | Novel human kinases and polynucleotides encoding the same |
US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
AU2002249854B2 (en) | 2000-12-18 | 2007-09-20 | Dyax Corp. | Focused libraries of genetic packages |
US6852844B1 (en) * | 2000-12-20 | 2005-02-08 | Lexicon Genetics Incorporated | Human protocadherin proteins and polynucleotides encoding the same |
EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
WO2002059325A2 (en) * | 2000-12-27 | 2002-08-01 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
JP4061043B2 (en) | 2000-12-28 | 2008-03-12 | 株式会社ポストゲノム研究所 | Method for producing peptide etc. by in vitro transcription / translation system |
WO2002059287A2 (en) * | 2001-01-23 | 2002-08-01 | Lexicon Genetics Incorporated | Novel human kinases and polynucleotides encoding the same |
US7582423B2 (en) * | 2001-02-02 | 2009-09-01 | Novici Biotech Llc | Population of polynucleotide sequence variants |
US20040142433A1 (en) * | 2001-02-02 | 2004-07-22 | Padgett Hal S. | Polynucleotide sequence variants |
US7838219B2 (en) * | 2001-02-02 | 2010-11-23 | Novici Biotech Llc | Method of increasing complementarity in a heteroduplex |
JP4689940B2 (en) * | 2001-02-02 | 2011-06-01 | ノビシ バイオテック,リミティド ライアビリティ カンパニー | Method for increasing heteroduplex complementarity |
WO2002065125A1 (en) * | 2001-02-13 | 2002-08-22 | Invitrogen Corporation | Methods and compositions for isolation of biological macromolecules |
JP2004530117A (en) * | 2001-02-22 | 2004-09-30 | プラエシス ファーマシューティカルズ インコーポレーテッド | Methods for identifying peptides that modulate biological processes |
US6875845B2 (en) | 2001-03-02 | 2005-04-05 | Zymogenetics, Inc. | Mouse cytokine receptor |
US7678554B2 (en) | 2001-03-19 | 2010-03-16 | President And Fellows Of Harvard College | Nucleic acid shuffling |
US7807408B2 (en) * | 2001-03-19 | 2010-10-05 | President & Fellows Of Harvard College | Directed evolution of proteins |
WO2002074932A2 (en) | 2001-03-20 | 2002-09-26 | Lexicon Genetics Incorporated | Novel human kinase and polynucleotides encoding the same |
US6644173B2 (en) * | 2001-04-11 | 2003-11-11 | Keuring, Incorporated | Beverage filter cartridge holder |
EP1383887A4 (en) * | 2001-05-03 | 2004-07-07 | Rensselaer Polytech Inst | Novel methods of directed evolution |
CA2446967A1 (en) * | 2001-05-09 | 2002-11-14 | Lexicon Genetics Incorporated | Novel human kinases and polynucleotides encoding the same |
US20020193585A1 (en) * | 2001-05-25 | 2002-12-19 | Walke D. Wade | Novel human transporter proteins and polynucleotides encoding the same |
US7300922B2 (en) * | 2001-05-25 | 2007-11-27 | Duke University | Modulators of pharmacological agents |
EP1461425B1 (en) | 2001-05-29 | 2008-02-13 | Lexicon Pharmaceuticals, Inc. | Novel human hydroxylases and polynucleotides encoding the same |
US20030113714A1 (en) * | 2001-09-28 | 2003-06-19 | Belcher Angela M. | Biological control of nanoparticles |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US20030148380A1 (en) * | 2001-06-05 | 2003-08-07 | Belcher Angela M. | Molecular recognition of materials |
US20050164515A9 (en) * | 2001-06-05 | 2005-07-28 | Belcher Angela M. | Biological control of nanoparticle nucleation, shape and crystal phase |
ATE522623T1 (en) | 2001-06-20 | 2011-09-15 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS |
DE10131441A1 (en) * | 2001-06-29 | 2003-01-30 | Henkel Kgaa | A new group of alpha amylases and a method for identifying and obtaining new alpha amylases |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
JP2004533840A (en) * | 2001-07-06 | 2004-11-11 | ジェネンテック・インコーポレーテッド | PDZ domain ligand by phage display |
US6943001B2 (en) * | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
WO2003012126A2 (en) * | 2001-08-03 | 2003-02-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
DE10138753B4 (en) * | 2001-08-07 | 2017-07-20 | Henkel Ag & Co. Kgaa | Detergents and cleaners with hybrid alpha-amylases |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
EP2153843B1 (en) | 2001-09-18 | 2012-08-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
DE60232672D1 (en) | 2001-10-01 | 2009-07-30 | Dyax Corp | MULTILACKED EUKARYONTIC DISPLAY VECTORS AND THEIR USES |
US20030073104A1 (en) * | 2001-10-02 | 2003-04-17 | Belcher Angela M. | Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus |
WO2005049075A2 (en) | 2003-11-17 | 2005-06-02 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
EP1840211A1 (en) | 2001-10-31 | 2007-10-03 | Danisco A/S | Pyranosone dehydratase from phanerochaete chrysosporium |
WO2004039826A1 (en) | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
DE60232688D1 (en) * | 2001-11-20 | 2009-07-30 | Univ Duke | BOUNDARY-BIOMATERIALS |
WO2003050914A1 (en) * | 2001-12-05 | 2003-06-19 | E-Tenna Corporation | Capacitively-loaded bent-wire monopole on an artificial magnetic conductor |
WO2003051314A2 (en) | 2001-12-18 | 2003-06-26 | Medallion Biomedical, Llc | Antibiotic compounds |
WO2003057921A1 (en) * | 2001-12-26 | 2003-07-17 | Sloan Kettering Institute For Cancer Research | Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes |
JP2005525095A (en) | 2002-01-02 | 2005-08-25 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
WO2003064612A2 (en) * | 2002-01-28 | 2003-08-07 | Sloan-Kettering Institute For Cancer Research | Identification of mutant antigens with enhanced immunogenicity |
US20030157495A1 (en) * | 2002-02-01 | 2003-08-21 | Padgett Hal S. | Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof |
US7078211B2 (en) * | 2002-02-01 | 2006-07-18 | Large Scale Biology Corporation | Nucleic acid molecules encoding endonucleases and methods of use thereof |
US20040025194A1 (en) * | 2002-02-22 | 2004-02-05 | Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US7662924B2 (en) * | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
WO2003072054A2 (en) * | 2002-02-25 | 2003-09-04 | Cabot Corporation | Custom ligand design for biomolecular filtration and purification for bioseperation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP2011886A3 (en) | 2002-04-16 | 2009-02-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
EP1497418B1 (en) | 2002-04-19 | 2012-10-17 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
DK1504098T4 (en) * | 2002-05-17 | 2011-05-23 | Alligator Bioscience Ab | Process for molecular evolution in vitro of protein function |
JP4753578B2 (en) * | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | Synthetic antibody phage library |
DE60319259T2 (en) * | 2002-06-14 | 2009-03-05 | Dyax Corp., Cambridge | Recombination of nucleic acid library members |
CA2487809A1 (en) * | 2002-06-18 | 2003-12-24 | Archemix Corp. | Aptamer-toxin molecules and methods for using same |
EP1543158B1 (en) | 2002-07-25 | 2011-07-13 | Archemix Corp. | Regulated aptamer therapeutics |
CA2494798A1 (en) | 2002-08-06 | 2005-01-13 | Verdia, Inc. | Ap1 amine oxidase variants |
US20040067532A1 (en) * | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
ATE466085T1 (en) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES |
US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
US20050064508A1 (en) * | 2003-09-22 | 2005-03-24 | Semzyme | Peptide mediated synthesis of metallic and magnetic materials |
EP2042517B1 (en) | 2002-09-27 | 2012-11-14 | Xencor, Inc. | Optimized FC variants and methods for their generation |
JP3447009B1 (en) * | 2002-10-29 | 2003-09-16 | 實 平垣 | Construct structure and method for producing the same |
US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
WO2004047742A2 (en) * | 2002-11-21 | 2004-06-10 | Archemix Corporation | Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
CA2506748A1 (en) * | 2002-12-03 | 2004-06-17 | Archemix Corporation | Method for in vitro selection of 2'-substituted nucleic acids |
US20050037394A1 (en) * | 2002-12-03 | 2005-02-17 | Keefe Anthony D. | Method for in vitro selection of 2'-substituted nucleic acids |
AU2003303459A1 (en) * | 2002-12-26 | 2004-07-22 | Applied Research Systems Ars Holding N.V. | Spliced variants of lgr6 |
WO2004065416A2 (en) * | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
ES2713024T3 (en) | 2003-03-06 | 2019-05-17 | Basf Enzymes Llc | Amylases, nucleic acids that encode them and methods for their manufacture and use |
EP1601332A4 (en) | 2003-03-07 | 2012-05-02 | Verenium Corp | Hydrolases, nucleic acids encoding them and mehods for making and using them |
ES2545639T3 (en) | 2003-04-04 | 2015-09-14 | Basf Enzymes Llc | Pectate liases, nucleic acids that encode them and methods for their preparation and use |
US20050250106A1 (en) * | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
US7964714B2 (en) * | 2003-05-12 | 2011-06-21 | Potomac Pharmaceuticals Inc. | Gene expression suppression agents |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
US7960148B2 (en) | 2003-07-02 | 2011-06-14 | Verenium Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
SI1641822T1 (en) | 2003-07-08 | 2013-08-30 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
WO2005012487A2 (en) * | 2003-08-01 | 2005-02-10 | Invitrogen Corporation | Compositions and methods for preparing short rna molecules and other nucleic acids |
AU2004261980A1 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody CDR polypeptide sequences with restricted diversity |
CA2535526C (en) | 2003-08-11 | 2015-09-29 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
AU2004280333A1 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
JP2005065575A (en) * | 2003-08-22 | 2005-03-17 | Japan Science & Technology Agency | Preparation of protein molecular-diversified population by frame shuffling |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US20050112585A1 (en) * | 2003-11-21 | 2005-05-26 | Dominic Zichi | Method for adjusting the quantification range of individual analytes in a multiplexed assay |
AU2004297616B2 (en) * | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
EP1701672A4 (en) * | 2003-12-19 | 2011-04-27 | Osteotech Inc | Tissue-derived mesh for orthopedic regeneration |
WO2005079363A2 (en) | 2004-02-12 | 2005-09-01 | Archemix Corporation | Aptamer therapeutics useful in the treatment of complement-related disorders |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
JP2007527246A (en) * | 2004-03-05 | 2007-09-27 | アーケミックス コーポレイション | Aptamers against the human IL-12 cytokine family and their use as therapeutics for autoimmune diseases |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
US7569223B2 (en) * | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US7785903B2 (en) * | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
US20080214489A1 (en) * | 2004-04-19 | 2008-09-04 | Anthony Dominic Keefe | Aptamer-mediated intracellular delivery of oligonucleotides |
PL1745062T3 (en) * | 2004-04-22 | 2014-10-31 | Regado Biosciences Inc | Improved modulators of coagulation factors |
US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
WO2005106012A2 (en) | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) |
US20060292554A1 (en) * | 2004-05-18 | 2006-12-28 | Genentech, Inc. | Major coat protein variants for C-terminal and bi-terminal display |
EA013993B1 (en) | 2004-06-16 | 2010-08-30 | Верениум Корпорейшн | Compositions and methods for enzymatic de-colorization of chlorophyll |
BRPI0514984A (en) | 2004-09-07 | 2008-07-01 | Archemix Corp | aptamers for von willebrand factor and their use as therapeutics for thrombotic disease |
AU2005282380A1 (en) * | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
GB0422052D0 (en) | 2004-10-04 | 2004-11-03 | Dansico As | Enzymes |
GB0423139D0 (en) | 2004-10-18 | 2004-11-17 | Danisco | Enzymes |
CN102746404B (en) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | To FcRn in conjunction with reformed Fc variant |
ES2323651T3 (en) | 2005-01-05 | 2009-07-22 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | IMMUNOGLOBULIN SYNTHETIC DOMAINS WITH UNION PROPERTIES DEVELOPED BY ENGINEERING IN MOLECULA REGIONS DIFFERENT FROM THE REGIONS THAT DETERMINE COMPLEMENTARITY. |
PA8660701A1 (en) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | SMALL AGONISTS AND THEIR USES |
JP2008532931A (en) | 2005-02-08 | 2008-08-21 | ザイモジェネティクス, インコーポレイテッド | Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and uses in inflammation |
CN101175769A (en) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | Methods and compositions for modulating vascular integrity |
WO2006099207A2 (en) | 2005-03-10 | 2006-09-21 | Diversa Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
CA2861310A1 (en) | 2005-03-15 | 2006-09-28 | Bp Corporation North America Inc. | Cellulases, nucleic acids encoding them and methods for making and using them |
PA8672101A1 (en) | 2005-04-29 | 2006-12-07 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
ATE515512T1 (en) | 2005-05-12 | 2011-07-15 | Zymogenetics Inc | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE REACTIONS |
US20060271262A1 (en) * | 2005-05-24 | 2006-11-30 | Mclain Harry P Iii | Wireless agricultural network |
US8389469B2 (en) * | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
US7491391B2 (en) | 2005-06-30 | 2009-02-17 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
BRPI0611714A2 (en) * | 2005-06-30 | 2009-01-13 | Abbott Lab | il-12 / p40 binding proteins |
US7582291B2 (en) * | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
EP2500354A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
JP5364870B2 (en) | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | Dual variable domain immunoglobulins and uses thereof |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
DE602006018746D1 (en) | 2005-08-24 | 2011-01-20 | Univ Rockefeller | PLY-GBS MUTANT LYSINE |
US7713689B2 (en) | 2005-09-15 | 2010-05-11 | Duke University | Non-fouling polymeric surface modification and signal amplification method for biomolecular detection |
JP2009510002A (en) * | 2005-09-30 | 2009-03-12 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Binding domains of proteins of the repulsion-inducing molecule (RGM) protein family, and functional fragments thereof, and uses thereof |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
PL1954718T3 (en) * | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
WO2007064972A2 (en) * | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
WO2007064919A2 (en) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2635692C (en) | 2005-12-29 | 2013-06-18 | Centocor, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
EP1987142A4 (en) | 2006-02-02 | 2009-07-15 | Verenium Corp | Esterases and related nucleic acids and methods |
WO2007092313A2 (en) * | 2006-02-03 | 2007-08-16 | Indiana University Research And Technology Corporation | Construction of open reading frame libraries and protein structures |
MY160772A (en) | 2006-02-10 | 2017-03-15 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
BRPI0707784B1 (en) | 2006-02-14 | 2018-05-22 | Verenium Corporation | ISOLATED, SYNTHETIC OR RECOMBINANT NUCLEIC ACID, EXPRESSION CASSETTE, CLONING VECTOR OR VEHICLE, TRANSFORMED ISOLATED HOST CELL, AND METHOD FOR PRODUCTION OF A RECOMBINANT POLYPEPTIDE |
US8043837B2 (en) | 2006-03-07 | 2011-10-25 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
ATE548450T1 (en) | 2006-03-07 | 2012-03-15 | Verenium Corp | ALDOLASES, NUCLEIC ACIDS FOR ENCODING THEM AND METHODS FOR THEIR PRODUCTION AND USE |
PT2596807E (en) * | 2006-03-08 | 2016-03-18 | Archemix Llc | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
CA2647277A1 (en) | 2006-04-05 | 2007-11-08 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
TW200812616A (en) * | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
AT503861B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING T-CELL RECEPTORS |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
KR101193722B1 (en) | 2006-07-24 | 2013-01-11 | 바이오렉시스 파마슈티칼 코포레이션 | Exendin fusion proteins |
CN101528766A (en) | 2006-08-04 | 2009-09-09 | 维莱尼姆公司 | Glucanases, nucleic acids encoding them and methods for making and using them |
EP2057465A4 (en) | 2006-08-09 | 2010-04-21 | Homestead Clinical Corp | Organ-specific proteins and methods of their use |
KR101625961B1 (en) | 2006-09-08 | 2016-05-31 | 애브비 바하마스 리미티드 | Interleukin-13 binding proteins |
US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
CA2663001A1 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
EP2617729B1 (en) | 2006-09-21 | 2016-03-16 | BASF Enzymes LLC | Phytases, nucleic acids encoding them and methods for making and using them |
US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
DK3101128T3 (en) | 2006-12-21 | 2019-07-08 | Basf Enzymes Llc | AMYLASES AND GLUCOAMYLASES, NUCLEAR ACIDS CODING FOR THESE, AND METHODS OF MANUFACTURE AND USE THEREOF |
US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
AU2008205457A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual TKI therapy |
WO2008095033A2 (en) | 2007-01-30 | 2008-08-07 | Verenium Corporation | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
US8143046B2 (en) | 2007-02-07 | 2012-03-27 | Danisco Us Inc., Genencor Division | Variant Buttiauxella sp. phytases having altered properties |
JP5675109B2 (en) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | Library generation method and use thereof |
KR101508397B1 (en) | 2007-02-22 | 2015-04-08 | 제넨테크, 인크. | Methods for detecting inflammatory bowel disease |
EP2124952A2 (en) * | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
PE20090329A1 (en) * | 2007-05-30 | 2009-03-27 | Abbott Lab | HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
WO2009000006A1 (en) | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
EP2172566B2 (en) | 2007-07-17 | 2022-05-18 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
EP2033971A1 (en) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application |
JP5933894B2 (en) | 2007-09-14 | 2016-06-15 | アディマブ, エルエルシー | Rationally designed synthetic antibody libraries and their use |
US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
JP5637561B2 (en) | 2007-09-28 | 2014-12-10 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Antidote to factor Xa inhibitor and method of use thereof |
US8486680B2 (en) | 2007-10-03 | 2013-07-16 | Bp Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
WO2009055005A2 (en) | 2007-10-23 | 2009-04-30 | The Regents Of The University Of Colorado | Competitive inhibitors of invariant chain expression and/or ectopic clip binding |
WO2009055656A2 (en) | 2007-10-26 | 2009-04-30 | Centocor, Inc. | Vectors, host cells, and methods of production and uses |
US8906700B2 (en) | 2007-11-06 | 2014-12-09 | Ambergen, Inc. | Methods and compositions for phototransfer |
WO2009088928A2 (en) * | 2007-12-31 | 2009-07-16 | Xoma Technology Ltd. | Libraries, arrays and their uses for targeted affinity enhancement |
CN104651381A (en) | 2008-01-03 | 2015-05-27 | 巴斯夫酶有限责任公司 | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
EP2706122A3 (en) | 2008-01-03 | 2014-06-18 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
US7682809B2 (en) | 2008-01-11 | 2010-03-23 | Agilent Technologies, Inc. | Direct ATP release sequencing |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
WO2009114815A1 (en) | 2008-03-13 | 2009-09-17 | Dyax Corp | Libraries of genetic packages comprising novel hc cdr3 designs |
WO2009132287A2 (en) * | 2008-04-24 | 2009-10-29 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
KR20110014607A (en) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
WO2009133461A1 (en) | 2008-04-30 | 2009-11-05 | Danisco A/S | Composition |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
CA2723219A1 (en) | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
EP3002299A1 (en) * | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
MX2010014358A (en) | 2008-06-20 | 2011-07-04 | Wyeth Llc | Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains. |
CA2728473A1 (en) * | 2008-06-20 | 2009-12-23 | National University Corporation Okayama University | Antibody against oxidized ldl/.beta.2gpi complex and use of the same |
CA2729949A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
EP2810654A1 (en) | 2008-07-08 | 2014-12-10 | AbbVie Inc. | Prostaglandin E2 binding proteins and uses thereof |
US8703416B2 (en) | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
EP2323680A4 (en) * | 2008-07-25 | 2013-05-01 | Viral Genetics Inc | Proteins for use in diagnosing and treating infection and disease |
US20100166782A1 (en) * | 2008-07-25 | 2010-07-01 | Martha Karen Newell | Clip inhibitors and methods of modulating immune function |
US9182406B2 (en) * | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
EA026110B1 (en) | 2008-08-14 | 2017-03-31 | Сефалон Острэйлиа Пти Лтд. | Anti-il-12/il-23 antibodies |
US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
WO2010047515A2 (en) | 2008-10-20 | 2010-04-29 | 광주과학기술원 | Bipodal peptide binder |
NZ593314A (en) * | 2008-12-04 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US8492133B2 (en) | 2009-01-20 | 2013-07-23 | Ramot At Tel Aviv University, Ltd. | MIR-21 promoter driven targeted cancer therapy |
RU2011135768A (en) * | 2009-01-29 | 2013-03-10 | Эбботт Лэборетриз | PROTEINS BINDING IL-1 |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
US8030026B2 (en) * | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
PE20121094A1 (en) * | 2009-03-05 | 2012-09-13 | Abbvie Inc | IL-17 BINDING PROTEINS |
EP3604510A1 (en) | 2009-03-30 | 2020-02-05 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
GB0908770D0 (en) | 2009-04-24 | 2009-07-01 | Danisco | Method |
BRPI1011160A8 (en) | 2009-05-21 | 2018-01-02 | Verenium Corp | PHYTASES, PROTEIN PREPARATION INCLUDING THEM, AND THEIR USES |
ES2605801T3 (en) | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor Xa inhibitors for use in the prevention of bleeding |
UY32808A (en) * | 2009-07-29 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME |
MX2012002605A (en) | 2009-08-29 | 2012-04-02 | Abbott Lab | Therapeutic dll4 binding proteins. |
IN2012DN02737A (en) | 2009-09-01 | 2015-09-11 | Abbott Lab | |
EP2478136A4 (en) * | 2009-09-14 | 2013-09-25 | Dyax Corp | Libraries of genetic packages comprising novel hc cdr3 designs |
AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
CA2775959A1 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
CA2778442A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
UY32979A (en) * | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US8420083B2 (en) * | 2009-10-31 | 2013-04-16 | Abbvie Inc. | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof |
MX2012006072A (en) | 2009-11-30 | 2012-07-23 | Genentech Inc | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ). |
CA2780069C (en) | 2009-12-08 | 2018-07-17 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
SG183333A1 (en) | 2010-02-18 | 2012-09-27 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
BR112012020373A8 (en) | 2010-02-23 | 2018-01-02 | Genentech Inc | isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent |
TWI672318B (en) | 2010-02-24 | 2019-09-21 | 美商免疫遺傳股份有限公司 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
WO2011109642A1 (en) | 2010-03-03 | 2011-09-09 | Somalogic, Inc. | Aptamers to 4-1bb and their use in treating diseases and disorders |
CN103097416B (en) | 2010-03-30 | 2015-09-09 | 詹森生物科技公司 | Humanization IL-25 antibody |
WO2011130289A1 (en) | 2010-04-12 | 2011-10-20 | Somalogic, Inc. | 5-position modified pyrimidines and their use |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
CN102958941A (en) | 2010-05-03 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | Compositions and methods for the diagnosis and treatment of tumor |
WO2011143562A2 (en) | 2010-05-14 | 2011-11-17 | Abbott Laboratories | Il-1 binding proteins |
GB201011513D0 (en) | 2010-07-08 | 2010-08-25 | Danisco | Method |
US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US9354228B2 (en) | 2010-07-16 | 2016-05-31 | Adimab, Llc | Antibody libraries |
SG188190A1 (en) | 2010-08-03 | 2013-04-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
EP3333188B1 (en) | 2010-08-19 | 2022-02-09 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
CN103260639A (en) | 2010-08-26 | 2013-08-21 | Abbvie公司 | Dual variable domain immunoglobulins and uses thereof |
BR112013008347A2 (en) | 2010-10-06 | 2016-06-14 | Bp Corp North America Inc | cbh variant polypeptides i |
MY163368A (en) | 2010-12-21 | 2017-09-15 | Abbvie Inc | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
MX344595B (en) | 2010-12-31 | 2016-12-20 | Bioatla Llc | Express humanization of antibodies. |
WO2012129347A1 (en) | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
EP3252155A1 (en) | 2011-04-21 | 2017-12-06 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
EP3574919A1 (en) | 2011-07-13 | 2019-12-04 | AbbVie Inc. | Methods and compositions for treating asthma using anti-il-13 antibodies |
WO2013016449A2 (en) | 2011-07-26 | 2013-01-31 | Indicator Systems International, Inc. | Assays for the detection of microbes |
CN103930781A (en) | 2011-09-15 | 2014-07-16 | 霍夫曼-拉罗奇有限公司 | Methods of promoting differentiation |
AU2012318609B2 (en) | 2011-10-05 | 2018-02-08 | The Rockefeller University | Dimeric bacteriophage lysins |
RU2014119426A (en) | 2011-10-15 | 2015-11-20 | Дженентек, Инк. | WAYS OF APPLICATION OF SCD1 ANTAGONISTS |
SG11201401791WA (en) | 2011-10-24 | 2014-08-28 | Abbvie Inc | Immunobinders directed against sclerostin |
DK2797957T3 (en) | 2011-11-23 | 2019-09-23 | Medimmune Llc | BINDING MOLECULES SPECIFIC TO HER3 AND APPLICATIONS THEREOF |
JP6336397B2 (en) | 2011-12-14 | 2018-06-06 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | Compositions and methods for diagnosing and treating iron-related disorders |
EP3800200A1 (en) | 2011-12-14 | 2021-04-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
CA2861610A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
CN104168920A (en) | 2012-01-18 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | Methods of using FGF19 modulators |
AU2013209492B2 (en) | 2012-01-20 | 2018-02-08 | Genzyme Corporation | Anti-CXCR3 antibodies |
MX352772B (en) | 2012-01-27 | 2017-12-07 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration. |
JP6545959B2 (en) | 2012-02-11 | 2019-07-17 | ジェネンテック, インコーポレイテッド | R-Spondin rearrangement and method of using the same |
NZ630020A (en) | 2012-03-08 | 2016-08-26 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
CN104394880B (en) | 2012-03-16 | 2020-08-28 | 大学保健网络 | Methods and compositions for modulating TOSO activity |
RU2014141018A (en) | 2012-03-16 | 2016-05-10 | Ф. Хоффманн-Ля Рош Аг | METHODS OF TREATING MELANOMA WITH CANCER INHIBITORS |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
KR20140142293A (en) | 2012-03-16 | 2014-12-11 | 제넨테크, 인크. | Engineered conformationally-stabilized proteins |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
EP2841951B1 (en) | 2012-04-25 | 2019-12-11 | Biodesy, Inc. | Methods for detecting allosteric modulators of proteins |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
WO2013174003A1 (en) | 2012-05-24 | 2013-11-28 | Mountgate Group Limited | Compositions and methods related to prevention and treatment of rabies infection |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9670276B2 (en) | 2012-07-12 | 2017-06-06 | Abbvie Inc. | IL-1 binding proteins |
CN104755498B (en) | 2012-08-31 | 2019-06-18 | 伊缪诺金公司 | For detecting the diagnostic assay and kit of folacin receptor 1 |
BR112015009961B1 (en) | 2012-11-01 | 2020-10-20 | Abbvie Inc. | binding protein capable of binding to dll4 and vegf, as well as a composition comprising it as a composition comprising it |
WO2014100542A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie, Inc. | High-throughput antibody humanization |
JP2016509045A (en) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | How to treat cancer and prevent drug resistance |
CA2902263A1 (en) | 2013-03-06 | 2014-09-12 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
GB201308828D0 (en) | 2013-03-12 | 2013-07-03 | Verenium Corp | Phytase |
CA2906417C (en) | 2013-03-14 | 2022-06-21 | Robert Ziemann | Hcv core lipid binding domain monoclonal antibodies |
US9194873B2 (en) | 2013-03-14 | 2015-11-24 | Abbott Laboratories | HCV antigen-antibody combination assay and methods and compositions for use therein |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
EP2968565A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
GB201308843D0 (en) | 2013-03-14 | 2013-07-03 | Verenium Corp | Phytase formulation |
CN105339001A (en) | 2013-03-15 | 2016-02-17 | 基因泰克公司 | Methods of treating cancer and preventing cancer drug resistance |
EP2972373B1 (en) | 2013-03-15 | 2019-10-09 | F.Hoffmann-La Roche Ag | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
CN105473605A (en) | 2013-03-15 | 2016-04-06 | 先锋国际良种公司 | Phi-4 polypeptides and methods for their use |
CA2914566A1 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
CN105408492A (en) | 2013-07-25 | 2016-03-16 | 巴斯夫酶有限责任公司 | Phytase |
WO2015023846A2 (en) | 2013-08-16 | 2015-02-19 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
KR20160055253A (en) | 2013-09-12 | 2016-05-17 | 할로자임, 아이엔씨 | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
EA031651B1 (en) | 2013-09-13 | 2019-02-28 | Пайонир Хай-Бред Интернэшнл, Инк. | Insecticidal proteins and methods for their use |
KR102344991B1 (en) | 2013-12-24 | 2021-12-28 | 잔센파마슈티카엔.브이. | Anti-vista antibodies and fragments |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
US10480007B2 (en) | 2014-02-07 | 2019-11-19 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants |
ES2806473T3 (en) | 2014-02-07 | 2021-02-17 | Pioneer Hi Bred Int | Insecticidal proteins and methods for their use |
CA2941693A1 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
MA50678A (en) | 2014-04-08 | 2020-08-05 | Boston Pharmaceuticals Inc | IL-21 SPECIFIC BINDING MOLECULES AND THEIR USES |
US10160812B2 (en) | 2014-04-11 | 2018-12-25 | Medimmune, Llc | Bispecific HER2 antibodies |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
MA51519A (en) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | HUMANIZED C5 AND C3 ANIMALS |
RU2016144405A (en) | 2014-05-23 | 2018-06-26 | Дженентек, Инк. | MiT BIOMARKERS AND WAYS OF THEIR APPLICATION |
WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
WO2015196070A1 (en) | 2014-06-20 | 2015-12-23 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
RU2733898C2 (en) | 2014-10-16 | 2020-10-09 | Пайонир Хай-Бред Интернэшнл, Инк. | Insecticidal proteins and methods of using them |
BR112017008406A2 (en) | 2014-10-24 | 2018-02-27 | Dupont Nutrition Biosciences Aps | use of proline tolerant tripeptidyl peptidases in food additive compositions |
BR112017007949A2 (en) | 2014-10-24 | 2018-01-23 | Danisco Us Inc | method for alcohol production by the use of a tripeptidyl peptidase |
HUE054339T2 (en) | 2014-11-10 | 2021-08-30 | Medimmune Ltd | Binding molecules specific for cd73 and uses thereof |
GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016106286A1 (en) | 2014-12-23 | 2016-06-30 | Biodesy, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
SG11201705721WA (en) | 2015-01-14 | 2017-08-30 | Brigham & Womens Hospital Inc | Treatment of cancer with anti-lap monoclonal antibodies |
CA2977026A1 (en) | 2015-03-11 | 2016-09-15 | E.I. Du Pont De Nemours And Company | Insecticidal combinations of pip-72 and methods of use |
WO2016172485A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
CN116333064A (en) | 2015-05-19 | 2023-06-27 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
AU2016270640B2 (en) | 2015-05-29 | 2022-03-10 | Abbvie Inc. | Anti-CD40 antibodies and uses thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
WO2016210395A1 (en) | 2015-06-26 | 2016-12-29 | Dupont Nutrition Biosciences Aps | Aminopeptidases for protein hydrlyzates |
HUE053619T2 (en) | 2015-06-29 | 2021-07-28 | Immunogen Inc | Anti-cd123 antibodies and conjugates and derivatives thereof |
WO2017011275A1 (en) | 2015-07-10 | 2017-01-19 | Nersissian Aram M | Factor viii protein compositions and methods of treating hemophilia a |
CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
RU2762832C2 (en) | 2015-08-06 | 2021-12-23 | Пайонир Хай-Бред Интернэшнл, Инк. | Insecticide proteins of plant origin and their application methods |
EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
EP3374398B1 (en) | 2015-11-10 | 2020-03-18 | MedImmune, LLC | Binding molecules specific for asct2 and uses thereof |
WO2017105987A1 (en) | 2015-12-18 | 2017-06-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EP3405478A4 (en) | 2015-12-23 | 2019-10-30 | Moonshot Pharma LLC | Methods for inducing an immune response by inhibition of nonsense mediated decay |
TWI756204B (en) | 2016-02-12 | 2022-03-01 | 比利時商楊森製藥公司 | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2017147060A1 (en) | 2016-02-25 | 2017-08-31 | Dupont Nutrition Biosciences Aps | Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase |
JP6987072B2 (en) | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | Activin type 2 receptor binding protein and its use |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
CA3019164A1 (en) | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EA202190162A3 (en) | 2016-04-27 | 2021-11-30 | Эббви Инк. | METHODS FOR TREATING DISEASES IN WHICH IL-13 ACTIVITY HAS A NEGATIVE EFFECT, USING ANTIBODIES AGAINST IL-13 |
CN109068660B (en) | 2016-05-04 | 2023-05-02 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
MY194619A (en) | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
JP2019521973A (en) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | Anti-BH7-H3 antibody and antibody drug conjugate |
JP6751165B2 (en) | 2016-06-08 | 2020-09-02 | アッヴィ・インコーポレイテッド | Anti-B7-H3 antibody and antibody drug conjugate |
BR112018075653A2 (en) | 2016-06-08 | 2019-08-27 | Abbvie Inc | anti-b7-h3 antibodies and drug antibody conjugates |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
EP3472186A1 (en) | 2016-06-17 | 2019-04-24 | National Hellenic Research Foundation | Systems for recombinant protein production |
WO2018005411A1 (en) | 2016-07-01 | 2018-01-04 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
JP2019534858A (en) | 2016-09-09 | 2019-12-05 | ジェネンテック, インコーポレイテッド | Selective peptide inhibitor of FRIZZLED |
MX2019003703A (en) | 2016-09-30 | 2020-08-13 | Janssen Biotech Inc | Safe and effective method of treating psoriasis with anti-il23 specific antibody. |
WO2018067468A1 (en) | 2016-10-03 | 2018-04-12 | Abbott Laboratories | Improved methods of assessing uch-l1 status in patient samples |
EP3535285B1 (en) | 2016-11-01 | 2022-04-06 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
AU2017362222A1 (en) | 2016-11-16 | 2019-05-30 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL-23 specific antibody |
KR20190080949A (en) | 2016-11-23 | 2019-07-08 | 바이오버라티브 테라퓨틱스 인크. | A bispecific antibody that binds to coagulation factor IX and coagulation factor X |
JP7274417B2 (en) | 2016-11-23 | 2023-05-16 | イミュノア・セラピューティクス・インコーポレイテッド | 4-1BB binding protein and uses thereof |
US11174295B2 (en) | 2016-12-14 | 2021-11-16 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
CA3046226A1 (en) | 2016-12-22 | 2018-06-28 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
CA3049114A1 (en) | 2017-01-04 | 2018-07-12 | Lauren O. Bakaletz | Antibody fragments for the treatment of biofilm-related disorders |
AU2018206552A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
CN110709419B (en) | 2017-01-06 | 2023-11-28 | 博奥信生物技术(南京)有限公司 | ERBB2 antibodies and uses thereof |
MA47362A (en) | 2017-01-30 | 2019-12-04 | Janssen Biotech Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM |
WO2018147915A1 (en) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
CA3052794A1 (en) | 2017-02-08 | 2018-08-16 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of plant derived insecticidal proteins and methods for their use |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
WO2018157027A1 (en) | 2017-02-27 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
US11746136B2 (en) | 2017-03-15 | 2023-09-05 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
CA3053409A1 (en) | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
TW201841656A (en) | 2017-04-21 | 2018-12-01 | 美商建南德克公司 | Use of klk5 antagonists for treatment of a disease |
US11236151B2 (en) | 2017-04-25 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection |
CN110603449A (en) | 2017-04-28 | 2019-12-20 | 雅培实验室 | Method for determining traumatic brain injury using early biomarkers from at least two samples of the same human subject for aiding hyperacute diagnosis |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
WO2018208882A1 (en) | 2017-05-11 | 2018-11-15 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
AU2018272054A1 (en) | 2017-05-25 | 2019-09-26 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
JP7269182B2 (en) | 2017-05-30 | 2023-05-08 | アボット・ラボラトリーズ | Methods to Help Diagnose and Assess Mild Traumatic Brain Injury in Human Subjects Using Cardiac Troponin I and Early Biomarkers |
US11654135B2 (en) | 2017-06-22 | 2023-05-23 | Moonshot Pharma Llc | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors |
JP2020526745A (en) | 2017-07-03 | 2020-08-31 | アボット・ラボラトリーズAbbott Laboratories | An improved method for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
JP6889328B2 (en) | 2017-07-31 | 2021-06-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Humanization method based on three-dimensional structure |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
JP2020536115A (en) | 2017-10-04 | 2020-12-10 | オプコ ファーマシューティカルズ、エルエルシー | Articles and methods for personalized cancer therapy |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
US11016105B2 (en) | 2017-12-09 | 2021-05-25 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
EP3721233A2 (en) | 2017-12-09 | 2020-10-14 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
EP3728321A1 (en) | 2017-12-22 | 2020-10-28 | F. Hoffmann-La Roche AG | Use of pilra binding agents for treatment of a disease |
WO2019133717A1 (en) | 2017-12-29 | 2019-07-04 | Abbott Laboratories | Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
WO2019160976A1 (en) | 2018-02-14 | 2019-08-22 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
CA3092551A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US10982002B2 (en) | 2018-03-12 | 2021-04-20 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
WO2019213619A1 (en) | 2018-05-04 | 2019-11-07 | Abbott Laboratories | Hbv diagnostic, prognostic, and therapeutic methods and products |
WO2019222226A2 (en) | 2018-05-17 | 2019-11-21 | Bp Corporation North America Inc. | Production of 2-keto-3-deoxy-d-gluconic acid in filamentous fungi |
TW202016144A (en) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
EP3824295A4 (en) | 2018-07-18 | 2022-04-27 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
US11548938B2 (en) | 2018-08-21 | 2023-01-10 | Quidel Corporation | DbpA antibodies and uses thereof |
AU2019334671A1 (en) | 2018-09-07 | 2021-03-25 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of PUFA in plants |
CA3110664A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
CA3110651A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
KR20230148273A (en) | 2018-09-24 | 2023-10-24 | 얀센 바이오테크 인코포레이티드 | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
JP2022512580A (en) | 2018-10-05 | 2022-02-07 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Compositions and Methods for Enzymatic Destruction of Bacterial Biofilms |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
WO2020104943A2 (en) | 2018-11-20 | 2020-05-28 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il-23 specific antibody |
JP2022507836A (en) | 2018-11-20 | 2022-01-18 | タケダ ワクチン,インコーポレイテッド | New anti-Zika virus antibody and its use |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
WO2020132557A1 (en) | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
AU2020208828A1 (en) | 2019-01-15 | 2021-08-05 | Janssen Biotech, Inc. | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
EP3914618A1 (en) | 2019-01-23 | 2021-12-01 | Janssen Biotech, Inc. | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis |
EP3938384A4 (en) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
US20220144934A1 (en) | 2019-03-14 | 2022-05-12 | Janssen Biotech, Inc. | Methods for Producing Anti-TNF Antibody Compositions |
US20220153830A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
EA202192508A1 (en) | 2019-03-14 | 2022-03-29 | Янссен Байотек, Инк. | METHODS FOR OBTAINING COMPOSITIONS OF ANTIBODIES TO TNF |
WO2020188466A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
JP7397884B2 (en) | 2019-05-09 | 2023-12-13 | ジェネンテック, インコーポレイテッド | How to make antibodies |
CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
CA3142580A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
CN113939531A (en) | 2019-06-03 | 2022-01-14 | 詹森生物科技公司 | anti-TNF antibody compositions and methods for treating psoriatic arthritis |
EP3997120A4 (en) | 2019-07-08 | 2023-11-22 | Research Institute at Nationwide Children's Hospital | Antibody compositions for disrupting biofilms |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
CA3161024A1 (en) | 2019-12-19 | 2021-06-24 | Quidel Corporation | Monoclonal antibody fusions |
EP4077658A1 (en) | 2019-12-20 | 2022-10-26 | Basf Se | Decreasing toxicity of terpenes and increasing the production potential in micro-organisms |
US20230061973A1 (en) | 2020-02-05 | 2023-03-02 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20230235310A1 (en) | 2020-06-04 | 2023-07-27 | Isobionics B.V. | Synthetic santalene synthases |
CN115867564A (en) | 2020-07-14 | 2023-03-28 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
EP4193151A1 (en) | 2020-08-04 | 2023-06-14 | Abbott Rapid Diagnostics International Unlimited Company | Assays for detecting sars-cov-2 |
KR20230042301A (en) | 2020-08-04 | 2023-03-28 | 애벗트 라보라토리이즈 | Improved methods and kits for detecting SARS-COV-2 proteins in samples |
KR20230084497A (en) | 2020-09-11 | 2023-06-13 | 메디뮨 리미티드 | Therapeutic B7-H4 binding molecules |
JP2023542301A (en) | 2020-09-12 | 2023-10-06 | メディミューン リミテッド | Scoring method for anti-B7H4 antibody drug conjugate therapy |
CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
EP4015626A1 (en) | 2020-12-18 | 2022-06-22 | Isobionics B.V. | Enzymes and methods for fermentative production of monoterpene esters |
EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
CA3204731A1 (en) | 2021-01-13 | 2022-07-21 | John T. POIRIER | Anti-dll3 antibody-drug conjugate |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
KR20230156764A (en) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody |
AU2022233792A1 (en) | 2021-03-12 | 2023-10-26 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
CA3208011A1 (en) | 2021-03-17 | 2022-09-22 | Sarah Harris | Methods of treating atopic dermatitis with anti il-13 antibodies |
WO2022195028A2 (en) | 2021-03-18 | 2022-09-22 | Medimmune Limited | Therapeutic binding molecules |
WO2022241057A1 (en) | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
BR112023024169A2 (en) | 2021-05-18 | 2024-02-06 | Abbott Lab | METHODS FOR ASSESSING BRAIN INJURY IN A PEDIATRIC INDIVIDUAL |
AU2022276189A1 (en) | 2021-05-20 | 2024-01-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
CA3222291A1 (en) | 2021-06-14 | 2022-12-22 | Jaime MARINO | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
AU2022308201A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023281462A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023281466A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
WO2023012111A2 (en) | 2021-08-02 | 2023-02-09 | Basf Se | Novel production of aroma compounds with ionylideneethane synthases |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
WO2023028186A1 (en) | 2021-08-27 | 2023-03-02 | Abbott Laboratories | Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample |
CA3230038A1 (en) | 2021-08-31 | 2023-03-09 | Hongwei Zhang | Methods and systems of diagnosing brain injury |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
US20230374122A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US4321365A (en) * | 1977-10-19 | 1982-03-23 | Research Corporation | Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules |
US4366246A (en) * | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
US4293652A (en) * | 1979-05-25 | 1981-10-06 | Cetus Corporation | Method for synthesizing DNA sequentially |
US4271145A (en) * | 1979-10-22 | 1981-06-02 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4879219A (en) * | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4362867A (en) * | 1980-12-10 | 1982-12-07 | Research Corporation | Recombinant cDNA construction method and hybrid nucleotides useful in cloning |
US4394443A (en) * | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
US4490358A (en) * | 1982-03-01 | 1984-12-25 | President And Fellows Of Harvard College | Screening vaccines and immunization process |
USRE32833E (en) * | 1982-03-01 | 1989-01-17 | President And Fellows Of Harvard College | Screening vaccines and immunization process |
US4366264A (en) | 1982-04-16 | 1982-12-28 | Stanley Wawzonek | Use of calcium metasilicate (wollastonite) as a formaldehyde suppressant for urea formaldehyde resins |
DE3303173A1 (en) * | 1982-12-13 | 1984-08-02 | Christian Dipl.-Ing. 8900 Augsburg Strobel | Method of genetic analysis and synthesis |
DE3300632A1 (en) * | 1982-12-13 | 1984-07-12 | Christian Dipl.-Ing. 8900 Augsburg Strobel | Method of genetic analysis and synthesis |
DE3246071A1 (en) * | 1982-12-13 | 1984-06-14 | Christian Dipl.-Ing. 8900 Augsburg Strobel | Method of genetic analysis and synthesis |
US4634678A (en) * | 1982-12-13 | 1987-01-06 | Molecular Genetics Research And Development Limited Partnership | Plasmid cloning and expression vectors for use in microorganisms |
US4719179A (en) * | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
US4959312A (en) * | 1985-05-31 | 1990-09-25 | The University Of Tennessee Research Corporation | Full spectrum mutagenesis |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
-
1985
- 1985-06-17 DE DE198585902946T patent/DE229046T1/en active Pending
- 1985-06-17 DE DE3587814T patent/DE3587814T2/en not_active Expired - Lifetime
- 1985-06-17 JP JP60502625A patent/JP2584613B2/en not_active Expired - Lifetime
- 1985-06-17 GB GB8628313A patent/GB2183661B/en not_active Expired
- 1985-06-17 AU AU44345/85A patent/AU4434585A/en not_active Abandoned
- 1985-06-17 DE DE3546806A patent/DE3546806C2/de not_active Expired - Lifetime
- 1985-06-17 CH CH85902946.4T patent/CH0229046H1/en unknown
- 1985-06-17 DE DE3588239T patent/DE3588239T3/en not_active Expired - Lifetime
- 1985-06-17 EP EP93116225A patent/EP0590689B2/en not_active Expired - Lifetime
- 1985-06-17 DE DE3590766A patent/DE3590766C2/de not_active Expired - Lifetime
- 1985-06-17 DE DE3546807A patent/DE3546807C2/de not_active Expired - Lifetime
- 1985-06-17 WO PCT/CH1985/000099 patent/WO1986005803A1/en active IP Right Grant
- 1985-06-17 EP EP85902946A patent/EP0229046B1/en not_active Expired - Lifetime
- 1985-06-17 DE DE19853590766 patent/DE3590766T/de active Pending
- 1985-06-17 EP EP01126393A patent/EP1186660A3/en not_active Withdrawn
-
1986
- 1986-02-20 IN IN127/CAL/86A patent/IN165561B/en unknown
- 1986-03-14 FR FR8603683A patent/FR2579618B1/en not_active Expired
- 1986-03-20 CA CA000504653A patent/CA1339937C/en not_active Expired - Lifetime
- 1986-03-20 CA CA000617095A patent/CA1341595C/en active Active
- 1986-03-29 CN CN198686102090A patent/CN86102090A/en active Pending
-
1989
- 1989-03-21 IN IN228/CAL/89A patent/IN169027B/en unknown
-
1992
- 1992-01-27 SG SG79/92A patent/SG7992G/en unknown
- 1992-03-19 HK HK202/92A patent/HK20292A/en not_active IP Right Cessation
-
1994
- 1994-12-02 US US08/349,510 patent/US5723323A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/464,327 patent/US5976862A/en not_active Expired - Lifetime
- 1995-06-05 US US08/468,477 patent/US5814476A/en not_active Expired - Lifetime
- 1995-06-05 US US08/464,142 patent/US5824514A/en not_active Expired - Lifetime
- 1995-06-05 US US08/468,468 patent/US6569641B1/en not_active Expired - Lifetime
- 1995-06-05 US US08/464,141 patent/US5817483A/en not_active Expired - Lifetime
- 1995-08-30 JP JP7243853A patent/JPH0856667A/en active Pending
-
2002
- 2002-03-11 JP JP2002066165A patent/JP2002325594A/en active Pending
- 2002-05-01 US US10/138,213 patent/US20040161816A1/en not_active Abandoned
-
2003
- 2003-10-08 JP JP2003350140A patent/JP2004089197A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1341595C (en) | Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques | |
US5763192A (en) | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique | |
SU1644720A3 (en) | Method for preparing antigen determinant of aids virus | |
US5750344A (en) | Method for selection of biologically active peptide sequences | |
CN112209995B (en) | Preparation method of SARS-CoV-2 surface protein receptor binding region | |
AU699568B2 (en) | A method for identification of biologically active peptides and nucleic acids | |
EP1220933B1 (en) | Purification of recombinant proteins fused to multiple epitopes | |
Panganiban | Retroviral gag gene amber codon suppression is caused by an intrinsic cis-acting component of the viral mRNA | |
Clarke et al. | pPV: a novel IRES-containing vector to facilitate plasmid immunization and antibody response characterization | |
US20030082514A1 (en) | Method for identification of biologically active peptides and nucleic acids | |
EP0109428A1 (en) | Cloning vector with indicator genes which have been inactivated by frameshift. | |
JPH07163379A (en) | Method for searching dna fragment coding signal sequence pepetide and vector therefor | |
KR920007684B1 (en) | New expression vectors | |
JP3335189B2 (en) | Region-directed mutagenesis | |
CN117567642A (en) | Recombinant fusion protein and preparation thereof | |
CN117384864A (en) | Recombinant adenovirus for expressing SARS-CoV-2Omicron Spike protein and its application | |
CN116970632A (en) | Recombinant plasmid for expressing SARS-CoV-2S protein, its construction method and application | |
US6946247B1 (en) | RNAse probe protection assays in screening for modulators of immunoglobulin germline transcription | |
US20040241684A1 (en) | Directed protein modification by iterative sequence insertion | |
MCGRAW | MOLECULAR STUDIES OF BACTERIOPHAGE-PHI6: NUCLEOTIDE SEQUENCE OF SEGMENT S (TRANSLATIONAL-COUPLING) |